ࡱ> _XYZ[\]^FM.Kb|JFIFddDucky!Adobed0M   #%'%#//33//@@@@@@@@@@@@@@@&&0##0+.'''.+550055@@?@@@@@@@@@@@@"!1" 2A0P@`Bp#!1AQaq "02@P`BRb ]<@ L L L L @ @ @@0C110C111101h)1 &4C4`X B P&mP5Djcd!a@&PH&*mP`P&`Li0L*V! Rm`@ R0#d)AՒ0@ eC(Ę&H!(&Į@`b*D b(kQ= @8hCa4Bv@d)l%04&1*BT)`*BJ@P$ 0 0C@m4($`0t֡7"$66M6L܉M΂]!*bW4KCB&m Ar%l̤!ЧD" &h&)Uȝ` \'rTԀW:v413UMԌMT L%h)rM&4CVhhM56Jj@C)$s)"DPB!bI5M%Ы;T 5'LJ!#BD , )dڵJ 3*Ն{gdM*cD[ t*P9lv(RCW7;D)Km\4!;B%N&SijQi Gu6-sIuPJѐKe"+455)qM\h7$Աԣl9lTERb)#L;Sj7\j@b^*d&H)sR"$4qBֳr+!M⦚t4b؆! i,őYɋ:NTCF2RK-ES&5Ahȶ!V!CWpk EA2YuKFEѝX)D<MSL0n*i)g"gCYZMUHf)5,WΤLVYUQ)H$ܦFѪLQ-t 2 IH ŠԄ!n:R̩X芫U()&i2hpCDZ!M9CHLcBZk*)8.H, CT;Lk-QkNtC"Dᗖ UJTR (*E@IE)T8n;D]2ɍr5͢"vRR:J(BШ:άj8)= t"I$&-F쑃N:{N$r*`K#MmidTy5-y [tT &^ L $hIHґr15rRPHLGSB D5cYBi (bmɝ͔ I+p!M(T H].I(cyҒԖ-R%jjR, R43f:TR ֔Lji̹Ji2t#+:bi:I/;h9rf:+sV$VtW;! j ℨbB*CYZ)LТ`ZI.t%g TU@LT8M^T8,ILE%W%EMAJySIh:$bo!zhpgA4rȡ*!ŚgHGM YY t*D h*RB\i*M!!%T(-<ǦTY()K$hJ!Mt)b!҂BY$RWU8)46p+TFD%X&ZB ZZMaQ(B(qIRr4!qPE6Efm4YTHZ$ڦuB03F`Ӆ*hڌ i RUC@FU&PEPjei KΒVfX4HDH$b*,&\cj"ª ""*P:F "QF1 HAjGQCΓR-E0mYN(s,kJUz,-HV ӚL\`E;j=3@, \ZrJnΔʧ Rh-Rgm IJ)(Ph!֒HES;@#d"(K\VZf`S0*5JjƯ;cj@A1jPA"ZH%TPMf-& R7H4gT(%-ҳpQK96#U t"4iٛmf)zeE^VLQ*mHyI[B42j%˜Wg>.\xsυ/2Ĺ~>g?sW?m~|*%isDRyy_sQ?GfyuG'^|TK_c?om~3'q#̦J'!:%N!rT \J*ua8,W(+L31YNN%qA>Z* Lsu"JOnd/Njl'2JTcp#*S\C )1'+l*\ RJ\9~)`$FWPH `ms?*V|*%FTuQT娟sSCTvbZK\LJ*אn|:SGu_=Zf7#fuz2St 4>3AeJJ^\RyԼzQgU`r]8(b<˱_}M Ϋ x\E`ΪXҷQB6@jZ@WS+2;Z@\_:aΫ2sͺ~,3P9~@%bKY\F*c-2RfRa'\93댧ZߗsF3p53#A'~0^ Ԣ<tY>%q3&8qST.V%f̙ͦƉՅF8nYJψ ֝M|\PK$KA̋A4 Wg/]8xtus®TLNVݼT:rVRμhƁBΦLS^SK ZWeKY|vtu9.gֺ u gý:sS9j%zG%2h:Os+:s̪;>+!h3ƙԈǯZ־q} 稢[-gfiYh9L eW|gj=N.ZW3|fgը|m$s54LeZYEX \{z.kh&u]L~ʣ\Lj+4&3g2phhih:c /^P{uXI8 sܷ.㾲Bkئys +ռN>spr0r Ij [i٪m. zĩH}면S48f1q^+=g]LB1?Fj&EWePďZ,xJ{К=f3η3,&r&lZӠ f!QygW]KC8rfi(Z3膝j?bkZ~ѓ+4)=s!ӧY3tc,Uֱֳ'f ޻KkkٜaeYgi sZI99ήvr:֜ۏV֬zs>EVU]3>PukZRS\^Gp tt[}Y2h3zդp̡3F yMTrN&CFIRR!fv\glE=k &Fu02J52g>C r #Lg ;^Ck0r3DW_9WNPT;0zG9dkݪQlbkZS׉*Ԇۭfjy\ǯK|䅩{K2ag/\KA)5si2+w ϯZY׻Y&l3u]f#2L3Z26GZӦL뙑dΖk-_۬c&}yusf:uc= Y`WJMoks4\..u[dkM @k[@/E{TӠZ[LʇRkNoA&7ˬuɕ9E!T}3:F :u~7٫\nz }73f&~!v&i5+C=o_XL4\8,Q;t=E2N-smҫy]iofܖ>p }ۂ&8p]/3J:׊+j}AQ˧3)ۼ`HLgZ+0ˤpjۂ\h"֗|| t3EIi=khVӟ̌vc>#ޥqtr|gZYs:6͹ Y]R/%:Rs;\nS} kڱLk&=iXsp%[Y3s_ 4崪qmQnWU0C'mS`%g GZd\ ѫu dz'gn]&4Oa3Td3bWD3zgejd<!?TuWKLZ;๜gJYx#6@Y'q7h͝}yˬƒi}?!ZUjYukgzLoZ@dkG\qY9Y֡zkt0&Bj~EM =L̜kjtz\g{>fd9fw; J&?LtdQm޸[gXL_jQ֋&NzMmRoE3zz.z#u,u 1NiMkc}rL=SLќ8Z8Yz^&Z&4taUtEsxijy jAL 82'X V{WPaPs5aheHz^X۝}=ymtiɽvqƺ&W[L:0¨ ɝ+32>i7sLk][U HR.bG-huYփGLjz[YiE]y=e'p?X,Wح$S6)w`\wXָ3kFsMk&~sbܜDUh2L]\榶ndXOY\OSg:IPLgmu{Y kZBYY7cז&f4[=z=ecttEΐOgM3 g($|UfhYD iLg&W5rkZרɐ57=z_^讳Q8ɜx[muvf[w32{3f:jvj^ W׎ hӲ*f >d5ՎΧ+*Zl pT70߱ ׳A7:Fpw NçHӭ:ukv ւvcJ2+zSH.DJ2t:20h1C]Mju\:z{k^ n PlPM}{K5Z\Q-[tGPwM\܋Hp~V}}OWK9 ` p:S1kZ3Ȼ -.oٝls?&yVg-ރLtAߵrU%C[ӤzΤbjcguLiEU^1nU ћV ?]S4*zItg}Wι\W9'5m0S@Jjh*h&yR'l.z{oO9oPRaP=Gc*ՙ,KE,-*S}5ut' ٸ"Egf;]b~jf9,2`!ɕ9 p]n bQ{tNՓY`֖tSZ3! 3t6tRbgV]$p2F_^lk3GaDN3fspͨVrCSԳ&X2ٜkMT׳]jdvNC^ͺskַI1r^ӌE֞]u%u.3;9̴2bm}]_c e֮dkӭ%?4<W 9 -ֵN4G49 EhT@!A9aUtr$҆yFj=`ZsTӘ23us82,CT\ ?Wn-r:=}M[mr1jV3M=ӧQthƙ ˒sz֬X%-]gU|odZ9˿c2-s5gfD\2kSy/KFRq[7öuvoפJ=~1Ss?Q7ˑPH )fɕEۧ9=sWfTifɱYɜQ9!o fg,άond~t̄!,Ĭ*FCy v|)ueIAm٧YxԳWĖt&!C&d@ofUϮ\\붷t}:cZzjSNRtI&WAհ9Lg0ݲNֵyװ,=giPu iΗ`Mf}uޝ`yp{]=(c7K%Z3`umJf193zkyxk|s91F; v9]1J&d]]ۨt+1׬4Fg7=}M_ѝӭQW)LQC [cgf Kk+3cY5ԃ{?5ۜ^Z3e8ζh'[/ ڂQ_RfulpXaR7Y>5~3Uu-bNˢtX煶hhgדZӦdY]6N;jg$:g?/56ڹ;';A+,zKg YZ24`&Fz9E.:ւkLtֻ8ˤPem1֟f9÷gWBR-^ڜ(ٜn̦f*N{@YYQ4n J4@3y0K:;\x3ev3]9|`퐷RYvO-&F;gkjv3/Zz(u3&G~VvkQOS&uPʺgla29ʱҹj gZgʠ F\f{d@Cvd&}zZeZ֟bޔE+ KI7vO#isl3H+35;֊jd=4{49LwåhS:Mp8*-AoSN*g<&>nA m^g3Qδ\d͙U9RM.5̔vtd 'S.6N@H te\vV3#fvjC-roq]Lu>~>sMN)ӓ$WZui1Lpμ-34k)Fknu֮uDX2^3g zW:ڦz2^ەnmhuRd d:nnp8q=σ9f@>ަyuYΪlL(-\.&_~us3}MCfuh-0g2+gx=9g!9=: oP3Pѓ׭1iZ18MN\l-e6sS󬼺7ty֪ Zjioј fwkJss8~֚sWY678}9Ү3zd4teSmƲ/Zæ7c|\g6fhX 3gétֵ j8>'ΉVo+֕1< .@Z2ёMYᅝ!I=hC_֑Uq[_Yzޓ}cKX]o&GJP S흐/SFQJEo9W띌 :GUε7ZB![55i)3v+P֕dє]mg]F:iMɌX0j13{{wnڿ_g ~׫ޔ+H붳IOg8Yg7ւ=m_:I'n7zw=@e+mOcdmsײgRe,4 *uSzN`ʍ̖zdM t&@ڀڳ\vQ4esΕ:[GP3_mVz##uikkFC+9oƴ˃ \vӯ^S.I%#3]reKW3Y׌5UP"AXGk[\d7uk(5{h*9Ajgmi]fhDk[PfB:QZS5iuf9sUh/AZbdq}/Յκ.sS) 0PuNdɭOYj|ƃNګ+3Wm=FiN@"ȩ.3%;d@M+3dəR v*g_ml5d /&]fz5dg[@&2vӕtk_>kzk kFQ\%芭Abz.E]/RgMN9)C:U3am2s[⺉,Wx.z:3z5gy 8&1Ψ5 tYwZtʏ&M!9Ӥ 粘5٥ Qu0ڌjuc9ˤ5پawf ^IdPJϪ2aDlk}ugBhV;It-P{fjM+ 2̔W*ՆJfsd4?̦ic] vjsu d}9Ur|%;/|z[ +Q֣˚OdOol&{ہKIˠ/ZwYE9 2UE_KYQg;G2ڳy>83 }WM!jLd@NibWEku?!.h7qLy}jJRȰSvX*C 9+Ygrj9Kc :ӧ[.ig%{=vW)bGtzM'Q|> `)sQSPY_fR3Pscۭ?&N{hȻј3P Ӑͯ V S{u uu]A;?6Nt0a`}g yY{-q:X4vm)u:XV&n.OBB:MwwΧ3u3χ>4GZt%S/KKs|̴W Ӡ?[Zt[w "b:VᴎOjEVH{.Py\jK b8sDF-M73WUHk9 4|`V|&AYDl.ߕZxekHx*ȷ3\8ounRƧ*\9vbs4itLD&P˖KOQV\x%Mme;{2sρ?gUy3;Em0Yrw?μ2~'i\[K.f7>`*Oy/*W x'5iep:Xp\, -JKeiqcaK.XBY/,-KX>gυ ϋU֝?GN =B:_ͱ]p<|Apj[.៝kWpj-˗ -Qbߋ ϛ|οo7[O_c?ޙrXoڤAr,˩dXrb_Fܹ|A,] ܾ{rf.eh-T *Q*T(J(~u+J /#ZX<~^VX/ })~}1}^JZƱ6/Q1}S^FY௢>'n " ~ִ/H%^Z 蝉xD/Q财/m%au^N(R,Y_(͞e*ǯ2 +l"$2B<'9֛H=Iz۶1 w.4 (󤔨y#Y[v1>Hf촲/lI1 HX,-<"YegYEU!6'b",Ouܲ[,b#(&%pR6z",̶@ƊIt( 7?*R<>Y"4Mg$x87vLi G''B,셄7#,z # ^FpGܻ!*<|U4Ydl>=W/mlD$Hu^M^œx+؄.HWr$?sXۤ]'81G y$|"OR[#Y"~G^Im.Gӧ?&l(^#28{U"헅Y)GUD< U{ݎ?RVY%r$Qt!.}vD%A#dm3OQy-/<b'%܍4܈Ȃ̞ p*'+ԽϔQ;rJn:q@^r4/ Djv|Uuݍ&u^rEOcFK'b'<7ek;w,r&hOɩd>%*%XK!C?/s.ǩ䗤uT1z.R!Po뫇dR> a TY de^k _rs$y=>]} ^i3/ m K)d^cܓ>7Y2F0ps w>*xX$Z%-F|Z ^IL?r-% -i,eID~B!<'O$`]R1,FB fbEScKG-^M-r?o='粖G W$uSu\lKV^엃0>3i}oZUU2z A1 Tߦ)&2F^zc&YHj)i$d|DK'`!T^G̓2yYUeuC>}U4ݶ?, f F L}(ne +KaW+!}Dnɑ$MdɊ!)DĒJV)8^ 1֓"^ p5 زVv"::^Ic܏>='Otz"Ϗ_r.ߑ!Agl=OG/YJc+{ pF`Dg9!T)݋b1b1l͍% ampz[ N4%lKT^gGe Qx~‡5OKW'|S,>p<<[dNt='',m-%^I$=Kg>=p"XđKj/_"Gė WW2Q/G4|zgI^ļ uge#?r/ݐ@I#@Ң&OGv8^zp|J1u%`5nW>K"X>8FEz-o[%DrK<kKVؘ^v= T=4mPr~N=kK(q/Vyx%]pO <ɛ Ƹ+rbH ~;ݐقVH{\K-bIc!`RBPK,)Y/,HDlnB? ?")~o2>%ɉkCK/F~ڸɚ/',|BSLoE剡)Z%'Bx)$=_:Dr%=7&kOb1,ull@B#KE zL6F{24Y=-$py&,ɛ9") b%d2J )^p&g>;#/-lD% D<]q6ϊB\  %9>S|GS3$DuvCgw9JK11DdU)G]d䅒ƕ!{K,|'=pR>H5/cI߱[mDvB"`A%m&4Hn/Qd ,]QBs|b,n^Ii-%H|V7eř|mTV/,Ci$4l] U/$K<4sI+'ɼ0%q"%KDU]/HHވƊ9L UM񶞂HuN+rJ\ !ܡ1:ppLKj[?!uرq+#u|3ؘ0DR[dnG0K%f)99&) 2z-pHp!-/,7%M>+ܡ9eFKtX-VɊ'n,F[%BX'%%A$Lz cyvOgleIHV^KbV ~Dc^4$xG!:&e('^9{8I I}nm[nN[""u:R"F$Kؽ*+,#mS.3m Ƶ^>)%g0Xt]UKeBҥ~670(1GirrK?:.X )!a7%id!*X8Dr# Qc O'XJVBPUlN|؄_bt!{Hd,E[ݑd|)pxe[!+/) $22nF!\KfD_Y(L$ X)DbIcs.2~Tgq)'d ƖNǁ=82':{2Q϶:>J%.7)ANz^ Kvxܯv"VĞXK>}<.Zxbo?bd=zX[igNK$u%ĐdutCt~Jȧ#HD!-du=DQKLݒǨ#_BK!HP[܅YPBx<OjE[$ 얆߰TğQ-=! 0su*D4EI JD|Xۢ6-A =Q=)x䥍ė)$!"u:rd_Tʢ[hIzHH\\rd+|Bnbl)nV CnngQ,e=^⶗-wnFUB'}" {"2VD`Ky>=.ܐJع& ҒJ>)D T u@#d'/HYnζGU%K#cX)y.>]{׹Diz6Og1 #FɃ2V x'aP (^g/bom[-0f{1dnpILOkdrJ'ɒdnN`L8=-K,GZ>*KoO-u>+ܕD䬓="p[!/ $H$}uE G&i:!8!)6KKqZP;VGd#t"4yGSO'>]+C?q%@o}t?g9!nI IgstZ$l``F?|>O'ѷɋ9zB]3BtIz#t9# %$߁,$َu'_y:rx.1[[BҶ'Β/B":u//؅ȥ4)r_n$AC{! ،dq=6{a'ۅ*.ZrBҶK<#<*qMu\iVF#q>n?#Jz^7#m% C>tKΒelY(n(d!aoLQ*,s 6Uΐ41N%!|V!c{L!g}>]^䯹nX4ް^ &䄨%J-؞E^HP䎾Yw,/$ox<I$x2^4pz <DF|z{9 ,//JP~GȏېrmAI7S-%)?' ,N,)$\Kܼ"{Vy'7>[IjY/ܡ<^OQB i .9܅x$"/|-lN BDrU-yjO$NF$b Me< [ik؎9"HE{g Q`>ļQ%))Ye[zL(d"<*-ؖGT>ݯU,Wө e~4luoqN^9.׭u4%s /bȖUٞ Vy/%i.x!nI' ,m۷]" z[^'$".o'& (Q}<:Fd6Y/; r?(ΰFM$9%pY.7*ˡ.KrlbXJϗlLFcs&Y Oٵ bHTOpB-EđY)zɒbtVγ2ynJhY-/Ư=(d%//bYCycOb!K)/-Eg,bY RzK$} n3SQ cmcbLd-+$,/Y(xҰf bXoIu%x%VBy'd4%;'8H1&J#a;Ę"`BJ,^^璈TK%kk^#G)pY &OmH$*2%躱xc\P9rz]Bd'\唰>ݷ'>NbuR7N|bK& RDI"{R Y"~p>k}{9gb^ \;~J#/:K#9XM𱤒1oqU2Y%Гs sGK6~%2Iv1//rd/("hXųԷIX-ޓ;QB!;O{!u蟗ૂ۳6ȋ3 b^u[w*cmHYgedVmqY?'C< iFli\*9b[&rP^߱J]DFD>K~!amO:yx,ܷdp9r.O{֘_'PlϏU<YjķODh3d =#s0+92{ ,g5'Ǫydƒܻ̕lL^C% /}rVH_qy,[,^,m,]zlm,v)rBB,dux(D/=Ks#J pLI.ddǡ,vEh=M#m<ˡs#_џbй&HW$!Y'/ Ix!k%R "OK!-!{K|^N|fX3$bEi ܫD$%c$$6%/Q!Ξ~ڷf4dZI>KYkB]A?KoRx(n/^^I&~ >CԂ +=~ޱ} ~Tk o/^OV_G/QsdU'J[*k~?_ Hkk*,WԗWgE?ӯ;je<ܩ77777777777777777777777777777777Ŝnd m>v:f33f U cmPPJCmp0712HsJIDATHKV[X$HWATyh( Ҥ@venn[X5BbKS{̜33/rXN(Eռ/p?mfP).bK%" w\g1Db$)II 5.< -BT%vl=eilNգ`;='{%\e׬8aP75n+UL)Jw;WLoսa<L .ms/^?uŽKLx H:ڎm1by2)\9}$[6[q(S{ǟ]??G)޲VTנ`T$ A;Hr{p⦈'#qCʫl!,xMꢊ$ U4צ+jv]d Vp鉝B`H0e},'B( Ҋa;o?`QK,M|E|#l]NCD%{qhe V"`k!BTH߱Ql W] QJP@dqma.1{I8CL0 nFčy?f˅ǮU [iNsQ̘I=lYI.-g dئt- kg%Mg01/z& cw!-_ $Jӟ:擝h9H\i@ewѨ)ƪJ"+ҨsõV+Mi8a\ @Όyݔ[~;2"[yCY !{1^)*/(ꅮ u9 HJ I24]9X0:Z{vf YNp>hť 5K}k ܑz3Pwij!ЊCB MnPuk`2,Yu{,l!/mȼ{DVp2X 0yڦIENDB`neMAdܝ?,@aPNG  IHDRD2sgAMABOxiCCPColor LCDx XSWOXeȪQ" T""UڐMBBvnuZQ,#Bq(bQP֊Tmա"9$;vBλ-N`# U* g.Y>0LD1^qؾw&kY.uz<qC c:%qG8S*bHbn"q,qT$ Nג8%q7̽ nKJ%\=/' 0ފB\cp8׀LGNuc>s`q5k/b0oĻQ] }{2Yvm2@L6tu 7]!`4 ~2pv&Oa9Lu1ks}|AsC _0rQ౱˖#N\ǏOHHLJ^2E*4=##3+;''7oU~~5k>^n isQ߷|u۶;Ν*޽{O?/ݷ?,?TQYE:R]}'jNߣ'u]O=_{jT|{?fR&{=]BMiзLCrFh蛉9,q#ʹx!:XJSw˝ƗP^񾉧ۉq5"=}َoOob;'m;5ܗ؎N|G˖оѾ h߉yķG2b|ͅEK >YCWZ'f6ڼ?aޜ'_NT(N#NUp]rM*Ɖﵿ[*Ʃ*WԸ_8ָG} vi#+8'pc0{VtkcAEU*VwS\tR`+Wg*G?:OA3r<{K$ݹ<{P-NJH2 DR I庰nɸzNȩ) pHYs  "tEXtSoftwareQuickTime 7.5 (Mac OS X)tIME 1L*A IDATx TՁlW W(d B0FO1IVN0⨨H䌯g>*'q2#LG ơQl@/\ݻ]vu맬fW^j2iu%^yҁ<ߟJ:0IAj "PhG<D 5y4@ͣAj "PhG<D 5y@>o4Sozn\3gk7gM_'i};ͮ=rѬ t'Af3偌e6-=KWw/1m}s#f{f_f昁G'ٻLռq纋߽߶a eM[T sϧ?[ӑe5F {ګG3g}`@A4_FnUog9FNz;m~gUЦeg ADZgw]%ڬL{C('65\꿔gӲ;B {Qݒ\̿m=?zڶ}i6̾|;~}a oM!5s3Zg @p06 W2!! cFmxlܺ=t2Bs^r[涇7߽r3Qa`?3nT ^ff^ٶ}W¡AFE}0=~q k-۫n.`Vh>tp¡|va~؆ǪDOv6maN`h@%%2i';?fd`T]-jMf^%!!䮧l4q|r'_w3+!w S]^+}P 7z;{M )56;bI#2k9`XL( 1l7N˛2Pc__=3 Af40Pm6yf嚷H\?3 1&% 5Gf;I״- ;p3em洩wf,k}E3E!!wjϮ/0ߌ;yxI^݆ɦe9Ԯ?yEJ <葂^!7jYZia4_<ִκmi7g?bhneymxi}b⮡m.so_Liy&B__M/t(P*czF3x@?`Gkk6lC^}~Wٚ ?pЎrY}ʋ&ݐjȔz_̠{(65*z{j Ul@AFǟiF\ɴs3s_`\3Om2j}}vn}{HRߦ8WWWW@A[UD݋_0o4+j)i["i]v{n5Emc8󔭱4~Ӳ;v o{|mCmnwWwtT̿-^>e;S7Oo|ݖ:鳩7=j#잫Ez "OZ#.pe^6Qf'G﹩(c=JpO5xHɦث6jCiJQ'hHO.4@ 5y4@ >>mvi M ZW/]mُIZBKA>D^xHkRuK&Po9ÏkQQ5 "Mzb1IԠܽw˴sL't k2=M0{lS effsw4MÆ:L[<2ٶcٴu}m~= ~lPma w]7.2/fz4虂7vkCzst*Pu9t[<Əa֫1$zKd5=d0 2_*j+>ԑfC-e# 5C @ֿL<$7=@̦<`VMںdĞTCSbGt$%ѩ;Z$)xHWF\t}ADckӟ8tP :l~˟?:f'  TݧW/3Qmuص)oL? ނU'}F7m瞽f -hH#GMzEޖ:O?Ts_H͍gOG4;kgp@elJ8X앤6+}A+AjsŔN)Ը7œQm;hۺM_SZy(CfYirJ@~l@2:<zFsYh?LCaЂ7vg&ݐ08HRYU5i-ԟHzav,]Cz?_Dto8hn{N˵LOAB ݬqkЂ6<ɬ}rADͼ.k߽ab1F$fv  ~ˬw^f'{Ѧ-;B@724~fbaa:R"0|tMP09©!!{݃WGjrW}y5ݞCWg贩3jL@4"W}/;h'~yM:+eP0W6ǘ9I|`z }]/9gԿ]V_4:(ԙft0LiM:@Y%ց紩wxIfC-IԸQ+DglLN^@r6P{jcvX͓6Qw/~;Qߚ*e9ITn :tY~g?gt_ "-_-s_q}={Ͷ˜qJ0f$խ[jq4<{](]j7@BavٗDWj/j+1TWWg:::JUj],r3o14喌e}ufQm2]d5g_Kӂn{Ƴ|j,z "Mzٍl__)tHWnPQcO[Xnh{ڹb< +44I3|ӃA9z9uG)KQV ЄѫCsy, ߗwcaͺNq̀c2+{bDq1nL4 0̼[ Y>3FQ,蓪ȼ탐+hhiS{XADs>0jA9^iiߧMU{=@ъd)g jvw.2;wyDF1\3ɄC*%h;Gmں#J އBv?{q蠐AaiM{YiؐA$x"uH3Ѽ/<ӦΏ74 sϳ hhfݒS".R'\ATDP >cBPoӔhL}/@ͣAj "PhARܒ&w{ !IѡCFl~/7GW]SmQ2dv>3wAz63ϚSG6_;fC-feM˂̞~dU]jmeoi9cHn\0ޕ)<1tV%2k{hҷ}nkmf7w\1FSWW0AzF3'!ZfokbׇYw\iΟpЯ~O8vYMm~\x%T " Wg5RpQmv3%mW9#ۛO)635 RҺ{ Rc%o$C ],2v4, Gg5O?~+Sjxsu>kga҂4W_8hݱۜxLN6-O.znuv#/SN4Zgvh@OAj_ݼ, eWnUmZPyP]WjWQCX )AD\}Ӑx Ao_d͸0cyS!-޽z}& "7O y$tBP^!h2MS@6ѬnVf5 @'A/hؽfߴu}:t,^N " _~DnIW9d02ӿQym7ngHR"}F\tdꎳ/0}cC C⓻i>y@?qPm'7=jVhVosiiٸQ͸ǎ(wpKC`r7m۾\3ɄC*%HHt%h䰡W .S#@A+@#jE#AcWPmD Լ k2MSnXv̔B C[fnͻ;v(҇$*HHZ7O"2M[!ef3|fcfݒ"&}Я>dP҂es>0醌ezX#W@R-ӦrymiWtlL!I'Un}L!h"M ?M:bӱ:wQmn'hH#Z:w'3͜*ہ{JØ:02hnͩƙFU` >̷n܊mֶv4ly7ͤkZMӔͦe+ViW5P$-䮿Z} ]uuhP!v_ﵛ/LnӭRh>Lew!]aAq9+^fZUC0b͌H4%ҕ^.*ԙdzش?Lܨ.JFUG L Iuk$=n]h~\CB]]5_٤G}JſVM7W^4!TC\~MߣX5VmnY2,[Q/q+vLжuyvr9eOċ̈aCJtܸ/S~3խJ 5_Wtpf~6|q6*̜cw-LZM`lyģ_S`CPơnLukD;wﵙ_mAiV_4XRNLϑl۱^=oArr)<*1'eSn1^z#+: t?=Af~[fI *w r)8ed)weIc_+:TS'Gr3aP?3~H0CR5[;nRuPK&? J=⚧;GTD 5?4Y3E''uҵ>Sh鶥K_^_j=;Ζ'i'oœOq5)}W{BA%T2ۏ6!r*HU/+-}"r(͕-\+[]b3zE3q<ՂQ 4Y!$Ss_k.9ˎX-MsmKvFI߾4.WM槉[ 7I&|f߁F}&JMI'~O/;)G76C̛ci>N^} U.y.ߌKKTt?wÆ ʁC"J^ZkG5O,,q>S !Z}?+-ZFsQ4]Ҹ԰*/]XtUG9[>_9eDcF)&>E43q IDATפlQ}_ʩS-hu2U~mS''M5bၓ>1Pk޲'/ѻk#l *E}1lݏZ%ۖ>wsj{fBQxj;/mfP-GD'eL#e͆ͩuJ;2 0ִl=ی^4J︴S\:mEOP򨆁oڲƏOyYȣjOU.4ZZN;yϻ.UyZVpe^3Gi3'"Zv aO_qSi bdOhR`]Syq=6ko\Ax+:z2[sfܨTM% _u*[̼l +U>/o:E9.n .Я0Ӳ)JV!V|5;vNпs:tr.uypsże?Ӷg^%3]o[jt?x[wie~Zxf}\3*m?ʁsdt\iʛ(|s .TBǕly=\s;θT8ϬXk~om޻1?J5n؆6LeE"z7aPzɛS-7.VmsmV&>i9[l&|䖿2צ*տotY pjھ iWW-w*}Wk~V3'UqR*wDB"+-|3g>T~Z+ŝ|Y6u5(*҉xvm* ?j?$lG2?BխJGqp|߶)gsq+;~uqjFi^JCڥ#|<3jɕty*n?!<`Dl&r<~9pu_Oƭo/[Z+U)$ߔ5w>Wv\$**>veGK\?`o~|on?Ո+D݄NMSnUdj/]x%5Gm˿Z}slcq\j{M/m; }3&_įJT| _t#Qb| M$owSr]rrGǣnNӭӗjF\ڎk`)e߇ZӺ¡L;uN{reH!&4*so=gzR闧ڵ>fuy\/dua\c+Xr.7w{'~?}TXGKrIFwŸäДօԝ~Q=Ozӈh6HR%y$d[f]{U{ȺP'Y>%0ZsڿuW`u{ږߤF SBih#ׯD߾sEm徧hT_5x4TPPK%+KmR)*/}A=<6-8nʄ>xCiq,^ŵʇʉZu\*G~kkOk>!o-+:N4O+O2Z.ڿ/3F٫Ȫ](g&x:S|f}MR}ӊ7(tL.~dm+;ϦQޚg;URO5 Q TLnK6^kOx=e+.%5tC4\R>}=wGi[H_I_reSoݏՏ7&f>:doۡu<JQ4ݬTؔ\i:^a_7.؁lƅ}<͟~|j[O8h(P\9ŕiݞTaɗr}*~ڶlO1#2 +T1*;]7~0DZ>lSEF*i7 u<~^ӾaVh~worՓQTn{ZǍWO+֓Kkqqc?θ=/;MV3uL t{\#~ō*mO-P]]@ r .Phz5^W[m&1ɠ j "PhG<D 5y4@ͣAj "PhG<D 5y4@ͣAj "PhGԼO4f̷ @@?4>ǘ&"K-3PhG<D 5QKK4i}睊SŋSL]m۶ٰgϞc4<+IyVQZfM|ap=[^sڕj)䫿 ǛI%bW9ҺX~a5]A^*W^m6mڔ#Gɓ'mmm6 MMMe GHOߡCƍ3sҾG1;'U|P.W^1sXaNuE5)\ջ*Ƴ:+;ZKGUѺ:3"իWlxB#:B*nvUi{&Lw\EomoժUSÜm[n{88PE+-/e?808p/%65> O6 OGx4ݢa.Ws[Aۊʎ>\ĝ k=ջwo[Vo߾J6wy]W}S]p=_6_S9wT\<3WdœCՏlaۙgS.u 9e?[. ۀ߅+wR˨_'ympztSDq7'8+;!~zՇw ޖJu%)HERGW*bŊ >#y---[nMo̘1Ȳ_;mk޼yIeSOZdI|`j|,aL8.:>Mm}֭4h=}'T&Lm+=R uwn-wOcccAQS#k<#. \S8c[zwwZ)v?q<|;cSig4>3y1iVi+ Oqcswl<Jb<%XHwb] r-WЋm)z V\ Z8[J!n?~sDžU9[s5O?O僸ʶZ:W0:wq'\䋛|=l?['~|Ŧ[Ka/*85niQ9N.4\^A6?_|e4[yKla+D "׀q\y미뗃hZ2]'[g\Du*otLR3v2˖-tiKuLꢗo-O(d%IhME^u}_?/n?Zsm{ݢJRŀPpꩧviJnQ>gˎCӹJ_u&WyN+Pjy׹WXnu?#b)nƂѭjRphܽCUfptsuteLmʨeo~jn[[w!臹8]dIAaԷHOVXѣΡ*.Oټys: ֢8/B@/W)fK_1~T4ݕQz: O~򓼝un 0T䪧+IZ/'WqSQ=&b{!kڿ5Mۚ={viQ~;S1q9V8àGs_mm7+E?LccceBYEj?j~{8b}ڏ_+VH/gyƦZhu"QA*7{y25}եԸ:бjlUJ4P$O9唌[TX@g!.b;WMuWHZvA*\ZW8|;T- FWƕB0hYȕUWk_v:1;N(n>eᡇ2oFFVu " /r.8jx [Fjj;鯌+5Dt-v?:^Wh\)nt`&Nh3 l*7ږ":.XUe԰S[ Kq/|vmqjq]<6nvn…5z.ZvQnBG;CQ7t0(]a*4(r&22ªLAﮂ蒣Z.aTwy'}I-A1σpzK0i}ro޽k:.wwqo}~;(r  wYqc-&?Omcѕ;?ic]5 5(3 Soqt]ov_~[C /.{TbKo_,r7Vh~߾}czkء ^:8 s)q'[q\fuR~dKlϖ>/ MBU4_ ϶bT.~oquY\\>Ȗoo+W=勋g?O[ۋSń?|qqV{#d+#r\]JUlͶh)BqlD&2F?ϷqiWd+Ի[Jv)bMa]FA;nIh!etF s\ڡ#QK4IiĘVET҈:zdH\2k4,&\;HkuplIUTjY#sUjtw#D* Py4@ͣAj^F;D^$=5PSg6+MaN-.ު!l&qի'BM定+bCyZR\jmzq5SSY)$Or^Qϫ)>tPOCqz yHNsR QsUXc$~xjtqdJ(gWLR\pSDew+YW#=F?p7+2c׸u3g)A p ҿK0f@h$U|z>Pts[[[z~+m-j]yB#ģ) 'ېr+of5ZqEǏB78_ݜy*z3FQ#7~&.=}Z~_q7q*ͣϒh?X~o82Y]G˖?'W^wǣe[rǧ*rnR@s)p]sBG43f̘Jņ-\=\K\֭ʁmN!8p'ZO0!gi{JKW[)$|XhvTs ˿qbh;W{̷;~=) 4“k~A7Q>[\k={РA=Yz]veG^~w;/v">\=Mv(gy&^ .hllsOo>=m?Uf^VXoXn]:t~hnŗ:iѩ&nݚoz,xu~ők;wLӶ4|AtE2TIҾSwǩmiѱG:.>(;**D[L9 =:.MsA9@@)/.}ueGa[dIhyVwu&?V]Wq]-wʨOOu=Wv IB:nui/-;)r'A!ĨB•#NueTts쿢zR߉P̟-NdΉZ).$obxa˵NDv o %_AbOq鯣L0_(n։cN.s,u4BΣz2z%[N1 [tlݻwW 2Y\l+),sS^Bq9iJ.i^r-e?Z'.tEsi{`Μ9rr$Σ7#t]T2IKD/x1zEO~0 YZ'U~'IMrwRw/mQ,ؕ(n;v@Ħo~F+&;xdIDATϚ2U"]S~oBW ?ā*VjU]LH jLp߾}Z?i ­X4ǍPtFEGecRI'$]hݥXekWDF+b,X`tu+ .ݺJ])؉ˇZTw?sH[h]?vIA6sʨ͏~C rtr[Qj׃ _n~(ë2>9rdz[he]YruC \CV\BX+tB)pύQ|&;+? BO+m\|!q\>qqPWB; >B@'[A} t<:YaRdexP^e\8pb?ܣ\7xcSSW|񙭎H/:^uArSH/j@ K7m/W#6.Qt?ƲC=T|Pv;'~(,<דJ>hNWh? UCzEYFi]Q{!Ţ,-<3-dxhd:;:0BQnȦ577^':~dۏOm+:lUvtӲh|fbǽGm [͵xÜ-;B<ŎӅAWqXc[1íky\y[Ӿ\#.lqq# O|Wt?-N䊛r(?sՓ S\Wrwa.llB/Rh􏧔)'Yku]B˜үݢ讣't`ڵ9 d]bwܞNFfrDS #ֺNF5@i^O8WT s!/l;%~[߲#k}РA 8 $\vef֭v%W3JkLUNP2z&)Ϡ{myu]>WLF0bIENDB`n&xU eʒu WqPNG  IHDR&PE5PLTEf3f`ZUSQMJE>uuvoop fPQXοkEFKLMRXY^_`eo&u"3},<9IDSKYR_Zgco126п=>B^_clxwǻͭӅ«ťȵʽru}սRTYSUZόPRVܖӿׅ:1L6ҦMW~GŒ0iS܍&wo L~¿5: Y.]Dzn._L~nCtcZf_W¿!Z?=eguԙi`ya8^8x0ı=sG/wh]MG_'v Qrar&…7ߩs1>Nx џ%xaN#iͼQGbc7GEw/۳F_8;.TT䑯ڏ pr%2L>y!C7Y^[,y|}O9`?N_:IDAT sTO`g|~r>q;-hya0E6GϞ=}vg8}|ހЫK &e3=zg?@Ξ?/Go>{ӱulm'OGEgO=텉GX_ $&6!,$4-5 ~v,lghw9"o[)??Lv|>='v8oX…w9#vGv&Ŝsrw;":8;tgرo&^iPYs<`r!//`cqA{|}}v~qgI찐]~{N>~q'}sgo@WBCCn9q/L"ndO;ű}S;qh{wmTsH߽߄neOr> ;yrW`xm{Nm;tdgc{;09~xg[JÉ Lv_C;%tsFS{31[B?>{`1H 0?vgo#CcwD 9pRt¡ 0 }̮-OVaOCB0y?Kn=%1Q}Lqߖb / ̺7`n}|v0L. =v,<v슉Dppw`xϷr|w a>`wc~;vȾ|vbs1 $|OP09r2><  ;30>#B"~`$0.7`WlxC~vFEOvol숎 J&_ =-pW}_#IDAT&;=t6?=< ?(Mϲ!'pw6I-ێ}b߮/. &EfGFv{|&A M' b7Gq'"$|vhb}=}b|p:;d5on쩨}_s Zv.;Gv~Dܾ=ġ} ۣ۷GD|}x}_ޛpn `V}l3Z>:_SȘ_߱sM#7s!$/?&>㣣ŧwX|0yODS_.|hg Մԏ3}z i֖Pm%MsZZ X;D2v~OA"՜O&em>Nl?D YT֟D]z,2%DF&ɒlھQGD.PvHF'|'{"Rġ-#kgw&7 GF#{=[z{,"nͤ㑑Q>;D~`GVy<_s:#F粅Ɂ/ak=C֙SaO4~̧"Nh-a=?pGC;{zo衘O7cǁeG 7g<(y bO(:;*`W?%yxӧ>_ kZaI1_???иhxqw2ރovƱb2UPIDATqzQ!MB rΗCn:p`sQ~!l>ܴo훶&c"}/?/| v6݄BϢCc#z8gm:l t&ߝ9} lv,}? ;¡нw*=3gcXFRú0@/$gb$#D:͆Y{4c}-y*]Və͑{s.̉cGbcl.e]a}!_Ͽgn>IP띟9ۗu-LG~ &6~cQ}ݿ#\wG|$:y'"6_#1`7 F̑+ùLbB_;zFӯƟ>u&>`q:6/@L v p8<4tݡ>轁pw{C+Hb_h\x#"S;bȢO &;'~wW_A]aQF>W{_Q"C?9qa6m{7$DJ&7/FąEH ]xB-b>kL|CA6Qa"<'no8Ց}٧mT@S{3r_X.oTցWEmtoOGAWBD,:Ѥ߻OFHhM䳯Ľ;#v$#zx!DsJ;C>[y;qIDATm1uض}^8m_SO|}~S;v/.o ۛ 'C>whȖȯCBC}.1{$l[ 937$.{(>,070*(8 6'BB|N 6Z~OOIxd'}>m'öDX{i$44v^@w !ՇiaD<$o@.?_}ោ^aW{ί x`oSe5ABGyxL}`4d*ߺLؖ&6XTЀS!m~4 ݻ3,:lsCܱmN s_?s(`54<*4ؑ^8-|9e[܅a.dhWam_d΀mqw~(ago-;vnK8vbo`=Nap=[b}âNX^0_ke@HxO!7&}N$ =~?D=Hpv]p}΀8;k/:09?!?RDؙ!'};t%!7x'. ]ǏA]p\yjaLΟNC$zt/D7X_WF~oזXp}n0H_D! 0v #?w߾/BAToݟ_M`cL>v*2 B1 #bCs;{E^was0]?[xS !'CC v0

~<$ *'&~fjP⏇K=F9aW{_~L ! ;B03dg.Ie![H` a(,7mz'İ{Sy#_=d+0BB>oWuuRq|{:x >}/{Dt</ޝ䯾8x"6: {8k.pxpq&Q >qGn>wQIpD` aŝ =ql[9tB'; ] l;a}V0= 0 6BIDATu ~"kU$ ('b[`88}ɾXplE-.n]dCL&_ܞ/bm&`79q\~6Cж-EÝm||n;0$22DZĖn$WaD#%!09ء=~Ljs_rl߶u ;$~+Rp)o=@h`8H$,tBw%099,Iɾӻ!boH\&&0P 0dHj8v*fo@`נN`rVaL>O:/viv$ -&qIQ۠*}G&7P- =b5 Hpi}?{+LOn ]ێd/v:L68 vP҅%{x7LsB` ; CD,bp w@wm*rCg?_ )t}_}؄}Q_c"N^\#"N~:NDg<p;j7_1Ã/8ƞ~,."r;)j:s""Թ 6z_EGl>&O';b"Ytb'=Yxā#{w\¾cgi;rlNF:{Źijܹ#QN? e{~ddĩoO n1p>q 8~;q:x>0ۡiO=gw?|y$2|WԻ;<M@G,[Ua/"B"NHݻO@Şѧ!=.f{n‚g*<7}.~ǹ ?`71bb~8I—1cl?gĀ3U{ޠP)3DtO^&&~͖k8eA&! }IDATMXĜ`LO6m?K࢈.|1{!?+\v;%'c6[iG(x ~p^~M|jcvDC1Pg?|z&6Gǀ-D_v;&օgIi~{!zjAsEm٘gN_v48a*uj^/c~vPVLtt2a 0A8툉>XlfCN] r[N>WKMĂu6p^B,'NR.Py(K҂PZMz{D= `ANGt(>2=p0sPM"OQlf_,G;g JC?aIܒbu2K0Ē8@DMZA^(R_ EϝJ5&y)V݂{&c=s=PG  /L/L$ >ӱyo{ ݀_Ϳ +u^Ax%- dpjTĘe~0a4Nfe!CY\4SGJ$pdA2:N vcS Bj%(ŎiTj܀m=ү&͛`ct7[ˮ=qUK ADj5TfjaztHY q-𠎭]Xد%bvQHWm^㖩qhW`݆8=,ahε;L9R0 xAf)jcgSfGv? -^tр`iF&{dYb2!z{^0 ף>qg[sHksXo.VHQ 3 q; &4!Izc@;HN`Ÿ@NLyMMhn`t 0Wjr-MXI$}ʤҼ ˜]*7L&jX/tOC&S>!mi¸ltJG}xW' W2G'Xxd ۢRҧX>ŨVh?5 ,@5˖Y1EG҄!7'Ó\LA;tOAfzcLn8L.`RH+E%UY} 5LpYRR1^'UuLG>!('LuB%;4{irQ+סh$j{mPf^~T{_@˰^ [*36-U)A*1Kw1td#-Pf*DiY@#E#+AAzN _+0sy2 'ky2?L* pOWP.f5йZIDATv@9FM"TZJp(&(~"mơ u\!z^C*oqeWL ̕S= =Ul%`$ݐ d(K]`"wݓ+y|s!' Ue)AbX߅5$x\b~Fчp`WQ{M iQo9 ,= <4DN 1gl~Z'@k_FO^r䰇I|KieSܟ52h hImT ׈1{+R$dZԷ L`A, fz#iHkHRĕR  YJX< cx8ɜZIu=ӣ^`yR`ScUީj\M^`#j=&_7Țr&Kw+4$ͤG1N\:xZEӂa~iY.$ S m$L{o5D}WBN*Ip`x( sN6RJ {p|:?D)1. 5 9u y a݋ DE'G*,~+R:޵yazDlsOFX0pμvqf&!xM}/PUsdGL&0*iJ3#=^$gR`rݽcI 2 Q/|4ڏuakbH n-#ya&8mp:JA(gwWRc%ʛrZ<̂n1UV7675ÛE=íPXF9e, [!$AУGSyABZ*rie7[Ki˦lUk(kwƕEصN0ـ 2IDAT"Us,f4xܚV B5 +gbvMT'VrTN촕utv {$_!ZibT[=V7XS &T,riEpuc.!&-A\z;Qa*yaګw:oB3hJQ9Q}LV&z0i0]GN SRavizfKpFa%K6^HH= +ExHAe3$ j"qb5`HCrZc7'6dž P6r+x8Pw6N6J02>4feK:ͣ}JOGA[mVXAKjSðN8g33Fm텉;0/m:q]έ!캖,h6ּV9cú$C/L܂dryr~kvZoݙN1y^Нu⭉Y $LRQW L< 7ue㬰UqI=[urrtu2P rDiQ?)ra,pi'j7\VɆci H)09)[x?q#*5yV9GWxCʥjͬ.(K]x 'GރɭIDATCUS̹zظxW͂v5$b/&^KE9-3_Lys(O6ɭ8Pm֯/ZrX$v+M<&.ӛ^?h7¤umzr&yh b4ଥLm?umq BY'ĐA)Y i0iGrk_ S#-4᫙}p cތT&WefԼ q:xaLD+-RK0#QT&Cj "|`4V-JjHHdF~ك5XEymeI, SgL;qJY)3k V If:vYvi&A(H8InSC ,8\r_]We&HdZ46Ij|WR--Jj{{G5-OVhdvS*M-ij0 $(?K0! @xT."g i6(LOJ=.`!"fyh0aQSw[K޵nt?+_.\dbKHh 5G)R-;%qսş|YL>29,c_|;5d)/daF  J\Ĝ[T@ HŨznL[ ljfp+pp(M 7%SAPY9<(Pٌ&4L( %htZ;V :ț)XVn.oƻRaiRi>cE(bz'&౎EAu,_<|IlfsXFL[ҝ(vjF})R ecT*uDX)7էjX yͩL%G0a) IxY8¦eEfhc$V" $GbT˒4B++~ڡ&C; f#? IDATu+%ɒ˛l\DY#/d"~+Dw%Lj[>Zy`zx#ƣ=h`ۆ$.tCERpmNJ(m& \Y„ؓ%p5i{o@tO $i8TjXXCS9V=%)VtsfF AN+T"ehVaAҫq&V1ssq7l-@*pϾ$Byr P". N3]>\/٫)49ajBo$nIj%ia2U2yA42SG|<pzJI-0a+2?[|=}J bVR {'R{:܍2CxHE{09 MpA?*'8On݇486fkU$=a2 |XyD&+=LYMHWM"&yH3:Fzs8iG^Ej|X#jT y}h0 s-I٦P \ QIL4B$qGаjBU88T56.q'*Vز2ΩM/F8F0IV7`y^fS:0D^Q9uJ  `փv֡$ZM55irp\ c(QoeuU5gn RsI˛_&LR'_â} {E+«®T&A يe5.MSV2Cid]n[b0+7`,\fRྋY@> %[8EV+k`:0q VӺ9EVۗlVfi +z& p H@eW e$@+Y dì *[5Rʀ zՄK[@Qm"XU0ii\]`xsbJ[*JꐷrpJI0h]yL+#*avjCLW@J W,^4@Ul] Z̿W`]rh.̀ǭ)jfnHM 5>v0HX )',p%J۳3>5u+6Y||%X!rKXg< !ځI1m íĆ<=&@J?0sdRfj'5*H0ad$F~R+MgRjIDAT붇IXdp.9ߘV+LX! 6aTMj$S*b90÷ZpI(TAH/SJBH `pM=E{a6*,ν7(nj R\gFUlIC4]TsRj zjfBzzj(o9ϧؒf& TfQZNZCl  IиL 7iz/%sQ8o3L䅉0xh!Ғ\cޫaPԿbGGZAz[wZV^-#B8K-,( bqJvk![r9V'_JVUHDsH?. 0q&ioy\@F.&KiUUDcYMѷwjmIYkͰLA][\U&BBH>]!"W9&[i1hYX9dxviB)ե).7Q )?8z:k!FqZN^f`nvWFNtC V&91r(1"[Ytc[Z8܇pRR0LVuC!ZE`6䀙;wI zgZ-pv3nd\Y9Rl0i.Mp"9qurd rʼ;kdgc`x4[Psz_8~bN ^]=IDATef\0q&x\ڐ՗{֣ە>OmHT2Ϻ⩇=L(_"xR3QGJ˳G?&y$7Z%nz,,*&vBJKVT]I^/G<|(\?x_Go~W\&`}#Jw 7L n+Rlr@rFAp.Y,IS\y]f9=sFmHmr܁dzi.myj0V+Uٮarި.=&+ʘ/u|]/L9MN|QN wT̾_I<@YE?8:gnKDRMbfE;îd;LH?z>hB|XR'*!M^蠐Dѩ3WNj>LbTTQV6>jgkb (8񵱠qʹb]rS% K- vIG"ˇ4rML0)jm&t5;Ih&OaTb=6a]d5[np*hkW҄&՚!YPr ([k5Bk`2nF)1˙fUP`R FIDATn")Ga]Q pi# ">ܥL z"niÍ =<|YT&cÔ}[7HRD8ChWmmٮaLIQJW V/b,ICrF`2I?Dj=B.н&ビ]4 \$,5!9)Rw ih ♡p|dxm&/6$ ∼ SA{)*l=j6vp4/PkLu73|iFzR t]!LI0\OaŸ5l~@<#K5b$BmD<W98H&LanAc ZMPYvIQRCCeL&YW.>5PK68ΪoW`C/t[HvA~ 4ծ tv0 Be;9cWVd.i ..F2^ִXϮ2M8ate7)'Wໆ$OKn= {PV"JI~UPܫA0cc]o uZ IJ)6<^ITÜ QVyF)u- L&r\,~tGtc8+5LMq%zZTTǘ4ZJIDATIW+5 /V`Rh (Y×KQ~u|ܲd:Iz0T+jZA(aj˻ںBD8 ΒKs!M<- xXڝ^<Ɇ P ]ԢS XцG_w6zъo!XQ̭L24혣ᦋqw2ڭ@57oRsqϔ;&XKa+J UkА78݅0픑z+{h8&K"(ۉ ՈZ(`XWqX\hU ehw$0au ulsJBu42ӐfzN;˛6i!Ȗ`9EٸW%G0 Xv\i9wՂ:;f3JJ9EDc;aL$H -Ζz>(ILINU ϓuRJ#ʚ*>N& &xqݷBe7': >*US 3d30_sx `VwL{:'WC%0wBhTAdYJʆ5vM9bqT rVEJ@S*q:z% o6ǹ-L2GqL_f  DS7ҞNc \ ׎>hV }kRP1wP1+9)| VIDATE20Y-,יU};&̟S [,Օ`=؀OXeRTp.N<_ɧ2)-҃u.h]!4ZpS H! DJI&;br0UuOWW~% 8dJ֒ )+i#`%];O`^%&pQ>!-/ȊK Hl#e msA6nLfɢa38b&LV!CH¯vwb yB?١)bJYNc nbA%&~Tlx[%[/LmÄ[8,@240WS = YCvD\Tgm&@HFT &i.!b$[I ($-L smo6S6`E!6)dc0)epQ PI[aH)ZǼ9!F0tYI^ ],Yf GnPbZ eGԟl#j7SIH -Կֈ_Xْ&0\Q\ju顤 =pT cǕYq& RkZl0q&iG8T  CMnre49 [ lTa% z Ǩ4p-l j=\MEjdYBe|iu^XB0vJ@%„9stϱT.>A 7wf}5fu2#4aE$Ћ?;b{4a DD&B%IR.X]4$JϘg`[9,&Ot@Z]XLv>:Q0a$i\mpv?VW8@ L@h=,4a9`V2,ۡvVk[&h|V'9a"4)5Ip$ش{*| hFd\hg"IDAT#Ղӫ` >A $#Wz؜D=2Ŀ>YVyhup9ya>d!G1Pӛ+`⸖K$@iaO;?Im+[!!E+ȝQb_bʅI5m'\L()p"4{WE7Y;~eA\+mW} w ć'n?$x ;Ulk%(1RE ڞ=ts^{cA+t:O ELmYN^u8ߺ8#  v`,v6Z\WI#(p`͓ⲍ"#sf5%w$^YD{l@g2٣ΟFk =*"E}e/jTlHŕ [u^7`RO7l#L6ꕠT؂ Ra^ek7qC@ ĺH ZNvR]®a%e')'V .kiQa9_`0Lʪ"v9nk^s0`68DJu:- [5G-ݝpbq<_R&vӵ%Lu\~Nnf46W6"/LS?P1#v'Q3Ir!M w %xuEÌ29T%^ΓEwHf;q9u楋ZRYJ84TD$4V𯛘nx[o0R?Atnt&\"a\;P"8fɂ8"o6\j$we퓦'ynEr̝ * v忔K=009H]42;lEvqӬr\+&'WJ]%7T"F2B,7F$pLJ@(uzH L:]oװ%M"x( >t< 8V D)1q#jJ1w$JAOI)%̟#ec7f=R-r3WZ; kG9J!6WarO!LгF-8(;L&>5hx !) 0C*iUHBzM: EJ4jx4$[^bi-,  (&˙vIIDAT)B3 ֔RÃ#]Z\Ib#|Z7H!HmI0nimrT - Z!(oDK<@~@6隧@5!DfITR<1nXMwZnnn0qF)fUOJyM`p ;&RMdqv\ k`anģ,:Jk\jl1u?ߠ[Nž}(K#SI0ٽoPm>Ib"V<4o5zuwB"{sit[ތѴ!LD3hNѿĝ*ؠdV,v9@ۋZ+˺w j ݟ0`0aR|8dnO| $]DKn]T@6)ͧs+g Ҳ,FE#[& kx&l2(p ' d`*@&VXIZa+M\-N*&g%f%.ǥ+ pVy-LaLy`)QX'! -IgP&@hYњ0;iRVRb̩-!X5NjN/͙Gvziԃg9Lx$}  ժϛ"XԢH" Z`RA9_*(֫Lip&@LğWYUs/+=WJ%h!м @<ܮ0y1+sd^>HjB9O!$Cuvl[i.I@,m qyFRSU3#Tl R-%Dz2&zC V^ qZ;=LXځ|%_;XvPKh.h뛱nݳg sM"f8I!%b$ ~j恣Ke0)]0˘Em#7&^u&@0y vVx%Vn!, *-G4LRHYp;oÄ3.UN9JʙW &b>LGI8-ZT>ax1̂F#gId^h+\xςf96Xk'n#; 9Ļ#i| vo+ H[² LWw.3xzH_%# kR+RfonbhAr1`i%_%щRL ԦCjBӭ L?=BaҾb &8<́KI3z\O[Z̚C]d&!"o':J.}HWd2X ot v52Mۖ?[ 0B 0˹_PͭYv2(+a”/̩t,<dM*sKZnϝ';uuG%L\͘M<-ڵyӒגj8SB= i)( X Q@[}|OKjec,HHo!&I:-uGEir9 ݦl\:#&$E'ӡMC)Ç&nf-Z0uTBq4ES.W6 ;JX2vSge)%SWOnEf'L٨3Hv/],D#$դD8o &5xiq aҦsa/M\e7|E>R7qvaLg c//y+YyepӁ!_j#CM'*fgr`qXaw-7+ \rM}@X,HKe;>s ~V$uZ\[N)6+D^H[g$`v)aQSfnܣʉ+E`u%?cp0(F.w& \G: &B5 Zc5Z6 Ղá>5Y ZfR7a? KNjӈi[}H| ʆ*~GhXƖBcc6yg9&4)!dQQ,esӪ] w=L4XLr>Tb͎-XM@g9ڊ>b6QzḒFP8j,6mP dmK'FMMMN-`C/a*c1~ڛ).nkYT+XGL E.*a+U}cl`4:k8KYzzZ]S؊w"L0;E%vRtX@^701g}CK E.]ph]pdfs"pK0E0с*8Hv +L $Tl?N!L_n `78E9wsbI`/g0d^Y)Md6;p.MLNjT R=]*.PNTS}Dr>n(aur|o,a 囖Z O0X8 |և\j1{pA=mR(75^e1^N;bj5$8tV^+rYtfc.nz aFWϡ4I%G86ԕA$,P0(ZaP|0%[1h.WuydxU& K ZO 87 ړHE~8Uosy )SqD:_vaטtVlliS'd?)#uNBlIJ}ДbRLj%76[bLj8w<)Zo5QOÄ>-Uiy PTqG2l0vٸisw'=Lr`Quk:!8vmOSB7IDATdW|? $  5? h`{aC&4E@xadr&\p ^{9Z8֐(MwsTL3&XCQΒ̔3iTȡ &]4j%+5{< “$f.W0;Lt\>`Nj@UlrKPGɪǘṶx}a"Z2ufIKBYjIL^.LkT vo&ѥA;NҵnBHQB-_%qGKŸl磿N%`"Pj۾,7uzϨA݆thepl{T6XGf=tyDL\R[rZ7JG,9SgIDBE qzd޳ٴ``r| #\$*yH'-4)h)ܸhB" R  6XepqI;a,KJ`#.dKLGQ/#OoA!>iIq+`hrdqD r*UjUZx"A S0EJJW-JP&: eGU*m=ardԩ*9F $vs-Mx/VC3ټ7Lp R6܎\2jƑ+@S] F(J2'C{mPK^n#<(7{2G"aJa 'z} ƛc ք2I['&R"ʜQ0~!-ba wGxX05k"C&B<CW0f- M fF: z-6 /~DbZ.2t8m q, Vٺ$5z$ "#3M\ohݶyazXMxr4ՉJzV*^%zXkZFG$epID gDe*Tleߦi\$v)dBZC V0f@;Z"IDATC6]ڜל~=iҾL;k{ b؋Ks8lb&ೄiRPtbP;j ,p<1E$,Hk0-ѝtXTY uAJ&j~䑠U ϢnX?9&;$la—0a5:t_MIQZp&KD&{r0)?Ҫ 7HI9u+&Zf*yeauM8d [$ʂ2EuU˜t)UBe5P^L=Kދbww~.|HM GдO!ؤ|tyV{F^ \{BR#BCjY}@ hwMKh9J]0IՀle% Pڟ$_U\Iܞ%Nca IJWY\HOv!BTL~8&dž)͘CK7$јAl8 I b!ӥ,BPcT #$ K2qӸ]iҮLPfC#Zln2UC>DZ¤g_-+~~σU;THJiXL&s"VM_8j#M/ë}IprZemœ1,Ѕ&jʒMZ ?AXc2uЪdά\E0jNpYh0 G]keh B]Ǝ&9fLвlPyX(ҸQ&|t*fE;XW:Lui8ϖVSE4YXX?/pj&Gcm9^d7rBM:7x}a;{.qcF٦!f>UV+/7``9z;cr&ۄɱSk9ݘӀ$\`O)o |A$缵XF0+gFN fj3A[qsK[[&GR/_jGUdMr/&ٓ#OK5IDATtvνVoVq,0K`*R`\gT^dfmI;009 a QrR*rI-Lz+`s&*,7Qz H'N+:f3|j@{@3idZ(d- _t@rÒ4ɱ[ L=XSALz8톳#CДUa$VyJ0щbr,yDGwnL9k39c`P 5g[W$rmzAfSYb1qQ6L&L<Ѓ&2$h>vi{`g*C:S)݀ۗ4F\c6ǃ=O6g.y]{i]q<2u0wԤ5[: #\-sh:LbYVR #C:!!PۀJd4 WWOLj#x`Iy%Ui ٸ'c7#NK;uOv]f5?xy*W(Y"^=k%nҡhd䘖_BYr"3 J~`u}UMPDyU$ DYILrE)AF퇘[A/'{CSȢMO oIDAT8lC*dz飗&S9l-㴧LEvLS87$ L]3?^(--2nIj9bg,3|$m+#nջLޞ}L΅jlYW|6JqZ z;nk{ u7a?~sg7kL5 wKb{h&?]ɱ<(//`~AcfWvZո7穌Cg Y? $v w}H;*Lez$u5&乐/%?hcjN)`dc+̥٘H2|a }0|ˤ 󂻺?& nC+LXyP٠=/8'k ٨LM M;F W#+MpoĽqϵ fncK\@F'8C5CK3I8ɳ96 \C rE1qɜ\R?36Ͼ%8!&~00IDl\Xnv/T@ŭrIENSΙ8-)Xگ?uѦ~-1͎ێ}QMKFi?G)II[_#q?%d)SpcR3.p@Z|Y\N'-ιtEI f30>Dֳ Ieq 2.aؒte @\], C.;8'0gRmP:eaKJ-oz[?;6q%~&-' Oe e|x5mɥa Iy,3{sY\dgMIDAT asx) q]X"@d2LCNIan-TsFg)U6{YBbKjܝNr\10ڞ?})`&'h\k=~ #N[zǒrG'ӣz H[&U5ԗؗj7ORpUxa%vo-*LmS+pFSèQL* Гv\0wjcv<ՀNist>mk5z``WKrh>kM~谥t+0QɚQ_[@()5I޾.hET8>.\!(}tJZ Ɔ +Pwn/CuqdGtUÙ勅Ũ[KBT.pD.o.U%Ş^$ ڗ9nVI[P'G5(hG*sHl}K{L YǨ_Ҋ$x`U.LI? m<7,Hs8ǜl2"TbFMMPZ%hJSW: M-1W;T]34h-HQWE*B}?/"q#sR sJ;H+OZQ=#y&pٟSP:ch7~g"w-bkI[$)XS"[LZLv t(q?T6Fل?L@#+M6k^b}bȨ*e9XΓɌ}< CMh+DҊ4Լmғ@s=Y^<5[7GL>^/:Fa]Ӣ"ygg3xOeeHADKp]񄲗B4& T'OuA& }R}1D,B {ğQIDATlҀjQw[MqՑo̖յ$jz`NBTCo1wY3SC<ܬKHC_TL3ptVԁ:_~Ԡ,ޚink@-V`2<=Xst gS)u\Dy.ķ4r3)N,]yJm.dPU-mڌǘVXfJᬆ#px|(8_ 'M`9q[[=mBVӐ9PF@@ g…S$QE _~"M:E8T-㮑z,Pw/c%=|:[foqJ3i(قL-BcQٜf1)nϸ ڸVi p/od+N flLJLSπ 5*~[s8O/S#n_h6Kra:OZzYAT_^g\У>ܣoVͩz^T()q#}A-C_<+F}IS[1kD4Fqs MEhk6M|}Ahw-Tّ.(iP;xÓü簰uO p8~ïZF^exljg"9V"U98L}l Qm.|o+|3!-Z ޢ6!.m`Nyݣ0mrXٛ`Xt\'a_?+ڞ..$g歠ww#9XƢG)VVKN3F ^tN@yF"2X֍㆖LM}DXvaVz]c;p>[Y8]R-HkZ&u-) \\V0nHN`)f6%3S p>NP6K^H*a!nZ!w=dUDj"6 3EI>g>L(~VVO<>H=jlIDATP YP0a~[*˺_"ׇ/vo?xa rE^!vg#!f?C;.G CͰi&^1^Xn צMerU3<yU/uX˪hN/L ?K񭛶s*v%ǕܼN÷0apNX@nU)?"U;탃0g_ttnFq+Dv,o/mJyiUx-\ JO,-rݼw_t:|*sӭk0%~yuDMrjCm9\4L@LrDĔ>#3^xGM?޺u*"#nG~lԌaEo޼uds-"M.ߺs+I B߉~ [ׯ^蟛nDt _u ֭P]=ԅ&9o^E2[[di84n[7yy}q"y} K40arG.]Ɨ6ݼnɕҥ;ೋ gH7*_,ݺv'Eܡ LMݥo^%?7a* ?BUW.c/PTOE7RMgmtSH~0w L_4]Kd„~v맟`nܰdux7]'/EYM?]ë E~ Yq~"&!\ 017on AVnP_W1՜KֺAYɦHCH!}rF` ]~$MJ0!Zń+01'-#& V&p­n^3/sW@%uZ[oxz J@**ʭ7ǛXF@rR]ŋN tIDAT֏7u|Ν3At`N?@ABCDEFGHIJKLMNOOR$.Kb|Mb$m>v:?@ABCDE@f   hnamd` Arial&Monotype Typography    hnamd` Arial&Monotype Typography    hnamd` Arial&Monotype Typography    hnamd` Arial&Monotype Typography    hnamd` Arial&Monotype Typography <4X(PK!J[Content_Types].xml (|N0EH-X tc HIb/yU8i{4ja&C+oU-{V~_)!bV䪻jև$:P+'5 = C 1{Q'0Q610x]l}I\JHY\@]^Q|@7J3|;CRMvGZah𩔑J]2SoNg3:~&UKM6o^PK! K& _rels/.rels ( 0nS=H^DtiUۛc a)hěBUrdk)Dd gIDr*dS("QlT3Q4b̜'օ9I]e3\0ťQ.D=vtr5aƓI+D#V0;f[e!/PK!tableStyles.xml I0@Ὁwh}-CQ$ +w*!@he/?JXd45ݤ{c@qqi` yߥ?" dd3??nAd33- ( 3"  3f n?" dd@   @@``@n?" dd   @@``PR   3  f` p>)$>%  g1_10(  =   ~Uw??Rectangle 2"PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!Nudrs/shapexml.xmlTMo0 tom'u-X]Q4-z[ɒ&)_#d]wdQG]]{ɶºNg)gBպԺO7ΜՀJT }pe0X5d>A`@w`4v E*O]+qyU!TbZQKqxClNqj/t29;T<eT=q;i6*葕rrDB:+٨Ż La{ XsסGPX "_jg%ޑܒajiĊ u;~ƾC1Ώ#51 5}I4:3 PK!drs/downrev.xmlDN0DHuT&B ueoɃbь,ףnYO7H `dJSI/|@$La:=Yb` 귡bb|s_֤mG&v4]ŕ!u!R1Ǝj*/-u7Û~IfL$x)X1_zTRHwר} '!Eh |PK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!Nu*drs/shapexml.xmlPK-!drs/downrev.xmlPK Ue!  T Click to edit Master title style! !   xQS??Rectangle 3"=7PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!qtdrs/shapexml.xmlUn0?'DZ A'1%J*I%AA&pUmu)o'Iԫ?>\8s^\(e )/' Y wnj4SjV:(TV'IJOJoQvS$.gZT({/3X)ɺu[pܘ;[86TڨifO֚m!E5#V .@0cDс*[l[H &R}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!s״drs/shapexml.xmlUo6~ڎ5ItS$QfH?;RNܢ(z~O>?|5Zl5JLaQ𸼺^& {·Oʞ JpL:d$J[ Ng} DڜFl3"Nb ]7Puȿ$*歷.jl&j^U ֧bոRݭ- ?j*u7je݋[G oGNI4 HY XʏLY;L̥H]i)Ͳ-PxOɵ}]Uߪ * A˰8QkG֭ܳ#!$,/U7sÈUc8&**7&-E[buOM~g9X bQxRK'EzL!71HkSb|G3 'ʗ~4*Xʚp么X^A\L̷ŢbC\>\uQ=nU Vo~5{λ˫y/ 6;&&&)䈫a5ucL*synX'"OJgI$|z1v-)]=nޑ[ ߺ~QW]|wǵb:^'.yGRWP%Cإs-MUazgBQ֘3EiXt"xì?PK!Ghdrs/downrev.xmlDKO1&暸V )DvDwE[a6nXzىB윕0VNux B,IPtp3Ri!6(MɗǪ%q<.L9 7? 1;Zh:l9_>Q.VBKԧ|\-?j$#1.oЩ DAB˶PK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!s״*drs/shapexml.xmlPK-!Ghdrs/downrev.xmlPK ,    hdman`  Arial&Monotype Typography  B C )   f?Rectangle 5" PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!5 drs/shapexml.xmlUn8}_`"_kT)`. 8E)H|RNܢ(~pfZt^Y>gT).f L)52?x}pyuͼZ¿4ثE='4A$uߟj B(]5KGVq]:ʌ&٘3#j}xҒyKGXbbS:¯`~p2@N{F6yݭ(=XVRf¡AUp`9_ZB1^zf_[hb\}.c!h4Cͦ)ls `2M9+1NgXr<iϮQ;\gD* ;Dڜ2v|9bZኙV5X'Jz۔% DΫ ܲ5j¤Rkz7`&=ssIՒ3~F,dLj+?2m}kul/a xY2oV8^غaaVMAG=? t ]E# ڇU8`xIJjZ00 x)m"6,/a(e40lAhبD޿vJhF'^  e-pN$YH e-"^ h eU8 Q+ };$B?%&\GrIQDF!d=5Xmi$xFVpu ?vV}l]=w|fQ1ިO1rMN6mjJB7*=!Q),O\6I=vjgzs>_aǸ$ҵ<-T_R/SelyUIC9Eϼ+>=S/ytva:Z ٿ Rt_"Q1{>qpYz?PK!%drs/downrev.xmlDKK1!܂;Tk)ӦQpw;yv\p[{ىB윕0 `d+:H(bBP;K^]^,PlwtڧeJhSj`;O6w S*9Í7B̸=ݷTF} ?/_V^ʫQYKԧq"#0y8N0& _ͦW?PK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!5 *drs/shapexml.xmlPK-!%drs/downrev.xmlPK ,     hdman`  Arial&Monotype Typography  D C    f ?Rectangle 6"mgPK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!:/ 5 drs/shapexml.xmlV]7}`"2 i%BFy̌gⱧs=,(%a{}w(I }Ld~LLJykęBgB-~U W x_mnd)SIRxLcIAj_u:v) oJV(--+р3-J{/S$vcı05LfiJgɉf"sCX5BX Q:%{Jߵ^Z,iv-psF쀜 D CnK 5gDŽFaGf^(u)җa{Px Αe+f(j~T{/ t</ X<2ɎtU'.jcg{+T-9SkJ^| ?_,_.麜2L~,g3lOMY Ы*%CBCzy8|j!;ڈJ~KA6*AN+DkB=f"ťXdT8PZNA^DTP:!hJCE̟B(Ϊ§( M2iR?*K'LFGgҷ7^6h2bng 7 1 +v91f}ytmp<R5UhD9t FCOeSM-Jx)l߆>cϟ>O߽뫼]IxLyT/j/9+tSd#bb tPK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!:/ 5 *drs/shapexml.xmlPK-!w:Wdrs/downrev.xmlPK\e,    hdman`  Arial&Monotype Typography  Z* C   %A??bcm_logoPicture 7bcm_logo" j  D?AԔ ?"  +T3f3f80___PPT10. ` PK!a[Content_Types].xml|N0EH-@% #{X%S5 Phwig[5gU-ܽTQ-jvsDbEcAJR#: "CrKA} >U^vy&󡔏$Eqnj9h\@ҕ]^> 7peJDl)'وk^cB:bR+͉- -]8[(W+MPK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!ОĚB!drs/slideLayouts/slideLayout1.xmln0 _H0 Bba@A>#+V 1^d;EH8D~"rg4kdIqvrZ0iLs"@;+'E+cq9}ny5n6r5eE- 祥 MYMlOe?k%7'FZ Aj@?ǁf!8qGO cI )E ]0#ύuVD2M^ehĠV[1mO9a,UlD'Q)F,t,ZX*ԒQY$R6~LCm恩*qz7zג/7 nt vڪMOr.wD(VE}b]PC#}trL\x:3ߥ'nrNx_NyLvfci w_]զW l̂P N_C=iG =3-f3#Cd@DX&cR8=Rj_S~d z^; - dMlA銂8Rn^7*6 )ܩpdN㈢.p4Z6RJ_*NHu<~냃x,^_Mrto>zMdt/M,/yVI!'}?PK-!a[Content_Types].xmlPK-!p8ܾ8 ._rels/.relsPK-!ОĚB!drs/slideLayouts/slideLayout1.xmlPK0PK!a[Content_Types].xml|N0EH-@% #{X%S5 Phwig[5gU-ܽTQ-jvsDbEcAJR#: "CrKA} >U^vy&󡔏$Eqnj9h\@ҕ]^> 7peJDl)'وk^cB:bR+͉- -]8[(W+MPK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!R% !drs/slideLayouts/slideLayout1.xmlێ8WwrR$Qh(c jǎl}I8v"n 寪*yt(u(8Σo/"<9WFyt.C9?{vG;l0pb'K>Jjm-Ovp8Q{9o6B_ؗRb]QV>}u'LY.Tzhou֦tWg6d%Y]"kk:,tXtܱ>V>$x?VS zRժZp^ZViGv5 ?50#찱g(;#Ց>qghyU쾾a+va= Sddt.+SV)'#^yRMz`3kj͠Gg]'%a241I&d:V%$*#qtOcM2GuoԎk3J*WPiZňq]Wr7ܿh4JPzWu۞DA BnA|8 ᆳ04J$~ ʼa2/<1b#}RKn9wI B}j~@2P-rgK(Iܗ7⠫ֹ%Fq:K$qNPFi-9.isLzϘs(ܝScJh<g?{ⴐ7:tYu6Di ,Q7'g`M@p:J*eHE_'E!i+aZqH #'Y^}C,xS | Kލ`z6!FPK-!a[Content_Types].xmlPK-!p8ܾ8 ._rels/.relsPK-!R% !drs/slideLayouts/slideLayout1.xmlPK@PK!a[Content_Types].xml|N0EH-@% #{X%S5 Phwig[5gU-ܽTQ-jvsDbEcAJR#: "CrKA} >U^vy&󡔏$Eqnj9h\@ҕ]^> 7peJDl)'وk^cB:bR+͉- -]8[(W+MPK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!`s!drs/slideLayouts/slideLayout1.xmlWˎ0W?XYV@ @#`NUi0`C#Mvb(l =a TLAD&X u mH05~k\BxqIJ9eNͥZzhtg"֫s<#$KN)Ie؀:r89ckD(fڑnhAT"\(51$.8 '񏅐  72VTSUƨl4T۩ϱ0$8wU32O~+@A!DLX00}h$7ԂD]|܊bPXjeP&*{gjcZ ȩE8+H9HGIzKouX1/=zNݙfQxUB1,Q#!O~+<)dTtzxMXfE&k 6f fg 7#F1f%XF&AXq~iKu "c1[p ;Bx,%<.d Ye3Lh*YFUjl@BzʵeF.^59nmA;iڽVTN'6fYRV8s+?5<6:mlc= 9vOa=SXSd V"`ؔ+˶,W\z %=D1ZPv igo%s^rLzKAv(kN8Oapq\Qa;͋3`_vMhж5mn|klG o5?jlV^^ݝ[÷\Gn(/{3rPK-!a[Content_Types].xmlPK-!p8ܾ8 ._rels/.relsPK-!`s!drs/slideLayouts/slideLayout1.xmlPKP)PK!a[Content_Types].xml|N0EH-@% #{X%S5 Phwig[5gU-ܽTQ-jvsDbEcAJR#: "CrKA} >U^vy&󡔏$Eqnj9h\@ҕ]^> 7peJDl)'وk^cB:bR+͉- -]8[(W+MPK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!3St=!drs/slideLayouts/slideLayout1.xmlX]oF}0Rր (ΪMUlb0q:36vxWj8s~pqSa:!'"t9VM-w?p[u>ЭX+ɔN2Vg+!K_XM&,E -}rtJm)\bߋ<8xx6w&'\e͞I6Q{/uAu@S zsiԆz (fCPoYp:Fڂ>^ h ^y2A6#mC/keh=GS"whǣaE.CiN CoJri-V4c']zG \}pȪؽ z@ȴ_.d-VFƴ,J O=Nrr'n2$PfjN 9ҊIWɰvX V+k}bUXgXۡgXvgXKgضAh| = mZ}c,Daʼn=}Eez+'*m$;u:t-\ɻP^S cѸvPFiq°}nV 8_guV7G#7õ#5~Zh5Ԭei|߸֑ym/ey ct7]3t뼆ڷ~k%~֟ VOYhԽUgz !a?PK-!a[Content_Types].xmlPK-!p8ܾ8 ._rels/.relsPK-!3St=!drs/slideLayouts/slideLayout1.xmlPKJ`ZPK!a[Content_Types].xml|N0EH-@% #{X%S5 Phwig[5gU-ܽTQ-jvsDbEcAJR#: "CrKA} >U^vy&󡔏$Eqnj9h\@ҕ]^> 7peJDl)'وk^cB:bR+͉- -]8[(W+MPK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!?'e!drs/slideLayouts/slideLayout1.xmlTn0?<pPu(F|m|\wIIND-ggw\ְVŤ͔3oy}򉳄0ީw*w i'dᒀ$BA9h3&oⶦN?VC~&vZ^rؓDet!lV^Cg!Oa" DFcWH/4mOщAj};9‚5Y)~5dmKdURUޞP%>C&qXvjFt(գss: 6 s`)(V`y'MT*\#uXŒԮ"M&y5l FU~dqE;bӭ@32KTo`j,@\fU܍rzn/z(PꃗĜ'Y~/O>#Y֜Áe7#>,<Mo] L5vFCmDN@=&k= Fs0 呡g!T;H3P*׬ ¯WYLM2[X^eD aٖ>iꢄ $sPK-!a[Content_Types].xmlPK-!p8ܾ8 ._rels/.relsPK-!?'e!drs/slideLayouts/slideLayout1.xmlPK{pPK!a[Content_Types].xml|N0EH-@% #{X%S5 Phwig[5gU-ܽTQ-jvsDbEcAJR#: "CrKA} >U^vy&󡔏$Eqnj9h\@ҕ]^> 7peJDl)'وk^cB:bR+͉- -]8[(W+MPK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!!drs/slideLayouts/slideLayout1.xmlRN0}G,?TRhSi,| 3v+bϜsf6(ڻ-9SNF].~qw棊r}z "/O<\P. *NYg>(G֣DWU y[S\./* I}jr`@cCݬ<a! dF~ 5щi}maAά;٠ ;%>S0dʀ__-jm W j#MXFcxAr; a8l&k' D+WG4 ľE^-}3$OL@naWs(XK < 4ЖbRxU@0d3PK-!a[Content_Types].xmlPK-!p8ܾ8 ._rels/.relsPK-!!drs/slideLayouts/slideLayout1.xmlPK{PK!a[Content_Types].xml|N0EH-@% #{X%S5 Phwig[5gU-ܽTQ-jvsDbEcAJR#: "CrKA} >U^vy&󡔏$Eqnj9h\@ҕ]^> 7peJDl)'وk^cB:bR+͉- -]8[(W+MPK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!Hn!drs/slideLayouts/slideLayout1.xmlWݎ6wrYih`nUivLbH:9& };1)aڋ?<~LUSo&b;>=D4)Rw`qwe\Np*S/Ӻ{*XAd6RTRE=zͅ׮W]&O2LD1N5쯲[t+zٕ,JPs%=SoDܺP䉒h&.hHĿmTt3 *j*_4̫]v4$B[ϣ%?V{XB,yJ-01B|uF4\) ZԿrY.]\/SCRxE `.oUi:'ј5Iu6ɾ\&/W=,8ncY6߹5gdpR,}KEƽvdgC_f 6T-yi𕍩3`܏± 0 ㋘0}7cEvG=2dz0]"$jimVИWziƸD(ߢ9SS՟SGt9wU4a)MP+.wU^vy&󡔏$Eqnj9h\@ҕ]^> 7peJDl)'وk^cB:bR+͉- -]8[(W+MPK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!"!drs/slideLayouts/slideLayout1.xmlXˎ6?Zp<{xdi8#v5-#c2Z|@~R-I`8x$>}p?&m6qƞcB2Vwc5\-L{;a'W8 \N.-2{Yn0 7L(RpW}^j؉lw..+cU0O[o83ZpγV& ΁a6c/*(Mj%qS, Dz, w*|!dL0BoSkuȭ0Pagh.YYηsb8 1p&Lqhs-Fg*'cͲv[o7S%A^\(ܫڟlx]14{֎~bkYX| _gdHP2+,9ʜyl`ުBc$ ׆vy# >X~KP\QJѽ':ԂQ{172]t(L]F;B!tt#.*R$ӢN"<C#]WE~F{݋n,-K*OSIf9fk 5P!d F" '7ce] FH}Q'X-Q"D-Zsc]Lr%DI.^h<, HJ د:#8R H(%8ȝ! ɄR^A!:]m=× +s+9|1C/LUSWP%`J9Ƴi}>IJfd4lé3~$էV** tĭɕZ:L Z,^ǢBo`+VҐk0:6nxKږS׍6p QR,_ժEԨuI[\D"h+7{ umJgck]?e!R ,6cLů `[4]z_v$VқXʲJ/&> p!KJJ>QszN0Y?&%- -|zxû޿xף;e ͙`U^vy&󡔏$Eqnj9h\@ҕ]^> 7peJDl)'وk^cB:bR+͉- -]8[(W+MPK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!Uh'y!drs/slideLayouts/slideLayout1.xmlUۊ0}/ Y凜b,[ { MY4qHdBB8ќsfh~qvΙUʮ'iq;YDhg儷27c_F]A6&FeQDQKyiioa]T~€J ʼn; 5 kf1pƏ3 J+l3MeOid.Ҁ(93.RH+ r2݀폩'jz:ŖG|JC Z2`%@b~L B~hf*(7RU01dN8W%D(^VEx V_DTPjM1@bǪ Js92g8'x_Lqfci ]&K͋Psl̂PP8=H~ i=i h 4x8J<3tLV =Dbhd rL CJ[ Wȉt2=THjrLr?MRq悢!躝S_R ΜxEB*:UwHFG?Rg;Yxz GfR'\ Gse#ّ ǣ_u׭.ju'!DwSk[e=&3M^KsE/! cdNPK-!a[Content_Types].xmlPK-!p8ܾ8 ._rels/.relsPK-!Uh'y!drs/slideLayouts/slideLayout1.xmlPK 3PK!a[Content_Types].xml|N0EH-@% #{X%S5 Phwig[5gU-ܽTQ-jvsDbEcAJR#: "CrKA} >U^vy&󡔏$Eqnj9h\@ҕ]^> 7peJDl)'وk^cB:bR+͉- -]8[(W+MPK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!ESY!drs/slideLayouts/slideLayout1.xmlVmo0>iI,(M#u4~m2;; U¦}1sLwRYǵ>FLQ]p]/y "bSg_޿܉#P.'S\zo$qd0Jn’-EDpoSYӭd !WrZ4IIb_G4}=TS*oJINvzO. +)04Qڒdw9f+v嫭g.|?ئK&( |˚%ݨb(CP@%RD0l磙3KXpPWkfnc5AI1 !9rߴH$߭MHC N$$7.-N BIrHʫ}`kPp࡮>V-j(>1%5A\-QUFZon?t5Jxi -WU:\^`0^ -MwtL M3ŌkXzk$`cA,`Y `fE N_׈ܣ<(R ' h *ĒGȁUCdȻ7@qsn BYEB8`%i HQ8гm?tWv|ςp)aq:2KX7$*qPtGk1!#[gւQ cJQ3%чQםZ_vN~t.<_Dyz'1@S+ m2p7c$` fPK-!a[Content_Types].xmlPK-!p8ܾ8 ._rels/.relsPK-!ESY!drs/slideLayouts/slideLayout1.xmlPKT:  PK!K[Content_Types].xmlj0Eжr(΢]yl#!MB;BQޏaLSWyҟ^@ Lz]__CdR{`L=r85v&mQ뉑8ICX=H"Z=&JCjwA`.Â?U~YkG/̷x3%o3t\&@w!H'"v0PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!N#>(theme/theme/theme1.xmlZ[o۸~_A^'%>@Y3-іE'N~3$eɎsi8h4|36M8F~ז,8[Wj"39d?|g:~Vi]Ȣ5/dg\BVOB%n!7MN:$q{H!JnF'A$Vq{mUr(F$#vqf}7Ys 3J3$O+y jⲼ5&_~gX^m/ q[b u蜓vRzVޖSܝMpö @lH`Sʜ_7*uZ"r`8LfI@gmY68M`mǑO|lH< yA;3ls܂i'4>&o.&+:n ]'dXF{=r;Q'lNsAdbsͩ6~ -i,d?Bvv o IJSR; ( %7,Ħ7* ,WWbj%5eaON|&۴a)J2SGX%bb,GD:R, V"Y8m1q1㭲Z잎Wf &g.7X]m/kդm30f!tk\tכ4N/1Xf^` C`#3,R#ܲeT$W;%Kb nShf9U@lhG⭎z`coS*Ne}e HY]#J4c1a|qs;ʤI6s|K߻=ⷔRR{JpE&0d$%poYoYw() on|X0ޢLTC[pLלAb1eRtxzs`gۼ>py<;=;RqH90ƏVxKѰ56Wnw:vjLA7;d_wvy;p bW3O~k⏟NqUw㊸Bͽ?stLwg>NmL?1>!`I W `қv`CRO%~w4`ZC{y$`*H(theme/theme/theme1.xmlPK-! ѐ'. theme/theme/_rels/themeManager.xml.relsPK]) #PK![Content_Types].xml|j@ 0Rܺc:IH޾B(!'Iza&C+W c+7oգT bV亻i6$XS)Ik2z  1{(Q'0?0mb(JUk^p+u# ˥x>V5PT]5 m rSϤq]J]_ ?*5GLRFPxΌNLn1\OR\hPK!*8 _rels/.rels 0DnzЃXmlo0of5OIw AN{cݠv=m 838yG 6U} ShLq`L)d=Ҍ\@.;3, ;$e͂): vq}j:zɥ'k茜(f,ƁXA6\m>PK! P-!drs/slideMasters/slideMaster1.xmlZn6wxµkY\ 腱5-S(ڋ{>ϰM mKjxA DdD!/ܥX^$ z ¢l}pQffhE fwy Ŋ€pBA_DsumqS,'8Bo ^? C~~Y'1)a _̓XGKc¥.^9&4+tfg~^D<+X{G2Hq#*T.|~VbG'4<=?>~x'2DD+&tiZȈ޼gZ~**R(|sL.g'>C Zĭ$TskwܞPͭq{ZJB5niq+ z[(߇qP#kzIkIytWH4l-l#q:T=$V6 iMn,ۨo~$X,0lm 6 2o."aR+$ Јj 9Mح3]\ڈWtq~+M0I@3*"V*uAH *]Pj}-p˴3`.mnU֒]џ^Pɩdf/%s/:6$P7O}yʖ`eWbYCǯM.,/krd1֪|U:_F;A//j_4[[g'ˇfrgYI]CXE.ڛͦ3t[/lgo~ؘq-21'|cƁK4)NQ8{"z>QV튚W;a"CyIcc+[ ;+W)\g!*p%4kuәm9 sY1sY%Zve7EÒ,+[A:B 3[Ě kӮMY-..>=PK-![Content_Types].xmlPK-!*8 -_rels/.relsPK-! P-!drs/slideMasters/slideMaster1.xmlPK Textured:R 0` +T3f3f` +T333FV*` +TNNt^X` +Tff3f>?" dd3??nAd33- ( 3"  3f n?" dd@   @@``@n?" dd   @@``PR   3  f` p>)$>%  00<00(  < < %A??bcm_logoPicture 7bcm_logo" = <  ~Uw??Rectangle 2"PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!Nudrs/shapexml.xmlTMo0 tom'u-X]Q4-z[ɒ&)_#d]wdQG]]{ɶºNg)gBպԺO7ΜՀJT }pe0X5d>A`@w`4v E*O]+qyU!TbZQKqxClNqj/t29;T<eT=q;i6*葕rrDB:+٨Ż La{ XsסGPX "_jg%ޑܒajiĊ u;~ƾC1Ώ#51 5}I4:3 PK!drs/downrev.xmlDN0DHuT&B ueoɃbь,ףnYO7H `dJSI/|@$La:=Yb` 귡bb|s_֤mG&v4]ŕ!u!R1Ǝj*/-u7Û~IfL$x)X1_zTRHwר} '!Eh |PK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!Nu*drs/shapexml.xmlPK-!drs/downrev.xmlPK Ue!  T Click to edit Master title style! ! <  xQS??Rectangle 3"=7PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!qtdrs/shapexml.xmlUn0?'DZ A'1%J*I%AA&pUmu)o'Iԫ?>\8s^\(e )/' Y wnj4SjV:(TV'IJOJoQvS$.gZT({/3X)ɺu[pܘ;[86TڨifO֚m!E5#V .@0cDс*[l[H &R}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!Vkdrs/shapexml.xmlUn7?$+!6관jgw+.%rAu|f9CΛw[v7c)\C!?ߜ̤lMYUȽ ů|lü+:n>jZ o\,|-E|QUP6RD֌NQK en٪nK/t]RXjNU` ڄ#{AXɣ r5KZQxyG LҭEw@YGT{Qyv<vpq4bQ>j>:0A]V縦n<;'ž3)EQ?O(*D2 #;'^ JA3JEL13gTjH nQr,N D&@`lҗ%aQ{S2> ?I OO 6M EL_ *l^;ls YJ/l\Q\UWqAA>u5uDɱILDR(U6tL4Us!a%?#'_".H~1I#HhTpO޾Mha& 8/Ӗ+Qg7ࡂmBW-(Ěr+MyRͷ0?z/[U(We|nKK픭 M3ʞ|^ሩ*t" ?2^o0 [%K$a%ˏOɤOT-s L_o[w:,gt͋/~X2]yjL\|`'ӳP@^ڨӱZP fdrJhVlo=Q'WqT#yAv`xpBwPK!]drs/downrev.xmlDKO1&撸/#uzmi+ ˓s|Yo8PcףqtǍDLcRpbvG^a!KTЦK)cՒ8r8w S:1í7E1;-zznZ}~u,}J]D}:\VZ#:Ƙ((n4[PK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!Vk*drs/shapexml.xmlPK-!]drs/downrev.xmlPK ,    hdman`  Arial&Monotype Typography  B C   < f?Rectangle 9"PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!˖WFodrs/shapexml.xmlUQo8 ~pAKdIb AiYȒNӤ~4pP%~>qi>(kJ^=LakeKdY`jȒex-cx؄+yA:ipK?r^i"D tԁ22۵[yv噪 B1a[)= NҊM =<`z/@0c?{̣h{J}Ƹ NZQ6#U%%.T+x8csf߶G\b=iƟL&I1l_|n6& LCQLg=|z g$|}5*Fܣ)S.C$b!(6#NL>5 ԉJgh&MHָT:R=?rk-PHC%6N YL;B+Słxo+βyqDžĥY;A-vwƮ[pDɾILDR(uc?tVsXԲ]\%#&]~HB62*SJ&{:A~_L&I%,ͥ$)kE:TA mqޙag"Ԃ+HU*T4珻M߰[WR3Tɼ478~rþjPOzPA;o*ӊ9\<q#U:Kn04^mpNg]3X5#U4~2h(JK"]+z[ېMTPkPcKZ1EDV q'?K6 ΰ \t`'Ѐ@@^̩(ki{RgV >Tpf ώٙ yvÆä>rieoNpPK!;mw9drs/downrev.xmlDJA@Дt 2$rf1&3oAUxś/GgŞRp>S 7 P>݀A`6 % TF ?PK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!˖WFo*drs/shapexml.xmlPK-!;mw9drs/downrev.xmlPK ,     hdman`  Arial&Monotype Typography  D C a  < hd?Rectangle 10"3-PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!b̯ drs/shapexml.xmlVo"7~kDHV 92ްkom/TTUUx=|3}NZWC33!_1g eLA:>W3\nR|}=v]pL-5 c+ᱴJ'*=J_)[KKRv[ZVpEw2%YV+^@0ֵPĿ[^`|pZ"w T(a7jt*m*)7zi9<٧|ގW_gxxɾ[=wLQ0ؿ'9gǣQ'Db"eP}d4䈄4kgiތC)4x*v )'dNp*Se{^7:TQ 1W&?5~SLc31G+nEr~Ҕebf__馚V |Yg+\LU Ы:##_[6<֬6GJ @_jA oTb.&,6&:n5=lRU.B &os4 ΈR{^/ P㣶 }eh? Wx=Y{|C9䘫eN !aCb4dQ O^{nfC)ӳ8ϋ[Zֱ\_rWU^vy&󡔏$Eqnj9h\@ҕ]^> 7peJDl)'وk^cB:bR+͉- -]8[(W+MPK!p8ܾ8 _rels/.rels 0Dnz x%ٶ6 (тqLݾQ(NAU ioo'tGHL m^W16 AJMȅ8a22~`Or[;,lij@搛}YMGBh ]pϔ{J Loc!"rPK!H!drs/slideLayouts/slideLayout1.xmlVMo6 t,>b/iSf8=mD'ݠȢC}|y3C#Iύ]Eɻ8"e~}-#bm+*UWё.tieuMs>Z[UT;ܲ7ԾSxSf? }F8>7Thobv;/u opIvְkyFVH铛~u-ǒf`FYsަl(+FFaVpM?8gĶsWOo wҺPKl?RpG$!8-ii )*^Y}o8Jm}kMk2/FB 7'O#suЄ.DwWog7n}){ N^ G#aʰ'4q\Ni=||h=h+|İc'>IHbsH" H$^qWLYQe%sh+lp{J=R cG L$t±6BYr8  s0[g pH|SF_ Hi  PK!K[Content_Types].xmlj0Eжr(΢]yl#!MB;BQޏaLSWyҟ^@ Lz]__CdR{`L=r85v&mQ뉑8ICX=H"Z=&JCjwA`.Â?U~YkG/̷x3%o3t\&@w!H'"v0PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!S(@(theme/theme/theme1.xmlZ[o۸~?AX .|Y-іE'N~3$e)ε `hșf8$]zWRUI׎<,$ߌ?/FWiG"-r9od}':~^k]U!Ȣ(egBeBVm"%!7K(I{ 6߅魒щ>M!?T-I ? R,UޕH~ G2o e@^w:菂Z3t@ky 㲼 &x'Zd`6j3S&w3ՖYEl=źXi&jINrOߔr-BtRDݐ =eI^-V2k: %kNtoRb%"MGcѴmmw4ݨOGj3MaFMe,lΆZÃnw{*/J?*4\"@*Y uJP'BVx.4zW+5X02HZlb}l<`:ѱ iN=FĈj *ͰWJ}/9Xx2mm6T4㭕C.\L0C[ٿ"[]u7G6*5ۮqOsXwnp L)t? }yzQ#zXy@;j@%HZ1D&eLkS_ elSLcETV,[6{M QnŽ沾X}X^mSЯJqg[]c uꂓn2zZގS܍Mpv A P$jbJe+d&r-V]SYx&$hzeqB3жC,[ X|wwqO'NT#6K,EtG9~|UEbnAH`SOEQ7WEtoc F azC7 XF>9o]ܨUIfR R1ӹL?E~ʗeH42/J;js \fp؁R{^Q ˄AIaSfb Z~ʒ+'>SumZOx)cvC#"Qr+o,d昺Y O'kАOW[.vvn6K}Z5amdŗuOy ,w.hClUrKnو2p^L&%) `g K{⭉z`֦E,"- %)ػ bرPdg0 Yg4;w]ⷔRR?=LzXJPݒohh:;c(whЦK4-S5gXL๡<=G9e(6em:C)O?maxR .W֫xK5Ѱ56Wͭ^o6L`؝d_w~ڝ[y䷷q bW3O~⏟pw㊸Fͽ?s i}: }(1~ `4rc|B&q0?y?CSO%~otF:SH qՐxBзEu0 toog~[D3LmiZ]T7PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-!K[Content_Types].xmlPK-!֧6 1_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!S(@(theme/theme/theme1.xmlPK-! ѐ'3 theme/theme/_rels/themeManager.xml.relsPK]. #PK![Content_Types].xml|j@ 0Rܺc:IH޾B(!'Iza&C+W c+7oգT bV亻i6$XS)Ik2z  1{(Q'0?0mb(JUk^p+u# ˥x>V5PT]5 m rSϤq]J]_ ?*5GLRFPxΌNLn1\OR\hPK!*8 _rels/.rels 0DnzЃXmlo0of5OIw AN{cݠv=m 838yG 6U} ShLq`L)d=Ҍ\@.;3, ;$e͂): vq}j:zɥ'k茜(f,ƁXA6\m>PK! P-!drs/slideMasters/slideMaster1.xmlZn6wxµkY\ 腱5-S(ڋ{>ϰM mKjxA DdD!/ܥX^$ z ¢l}pQffhE fwy Ŋ€pBA_DsumqS,'8Bo ^? C~~Y'1)a _̓XGKc¥.^9&4+tfg~^D<+X{G2Hq#*T.|~VbG'4<=?>~x'2DD+&tiZȈ޼gZ~**R(|sL.g'>C Zĭ$TskwܞPͭq{ZJB5niq+ z[(߇qP#kzIkIytWH4l-l#q:T=$V6 iMn,ۨo~$X,0lm 6 2o."aR+$ Јj 9Mح3]\ڈWtq~+M0I@3*"V*uAH *]Pj}-p˴3`.mnU֒]џ^Pɩdf/%s/:6$P7O}yʖ`eWbYCǯM.,/krd1֪|U:_F;A//j_4[[g'ˇfrgYI]CXE.ڛͦ3t[/lgo~ؘq-21'|cƁK4)NQ8{"z>QV튚W;a"CyIcc+[ ;+W)\g!*p%4kuәm9 sY1sY%Zve7EÒ,+[A:B 3[Ě kӮMY-..>=PK-![Content_Types].xmlPK-!*8 -_rels/.relsPK-! P-!drs/slideMasters/slideMaster1.xmlPK 1_Textured 0 80( regr4 8B 8 s *޽h ? ̙3380___PPT10.pZK'PK![Content_Types].xml|j@ 0Rܺc:IH޾B(!'Iza&C+W c+7oգT bV亻i6$XS)Ik2z  1{(Q'0?0mb(JUk^p+u# ˥x>V5PT]5 m rSϤq]J]_ ?*5GLRFPxΌNLn1\OR\hPK!*8 _rels/.rels 0DnzЃXmlo0of5OIw AN{cݠv=m 838yG 6U} ShLq`L)d=Ҍ\@.;3, ;$e͂): vq}j:zɥ'k茜(f,ƁXA6\m>PK!Z\!drs/slideMasters/slideMaster1.xmlj0{ˍԱ&Sڍ v(r,?FRf 6M&Wؑ,v7J/Vhr%E'KGWR˵Jqň)\RcdQS"b)^0F_:s , eܹ" Ks&SЖi#SC.AZ v$\zyxe%Sn%b os^صO\̋ղ -*_2eF%:SΜHBR $M>̔6d"#YV ̔9'sǬoJެ"Ul6DOUmOQD )xɉ:2U9V&2rfgres.!4?Kt%(+1\,R #cYS Ii}Cw_ߗ?77/t(# I ]UY]S3@1!ORVFnqoP[i'Vm 5=۠Gqyd5^5ON8n [bT% 4OR­VC"Hx{Wj ^;/xyWjAޝb 5 ۋ5ȻYxU$̬aи~~PK-![Content_Types].xmlPK-!*8 -_rels/.relsPK-!Z\!drs/slideMasters/slideMaster1.xmlPK: W PK!K[Content_Types].xmlj0Eжr(΢]yl#!MB;BQޏaLSWyҟ^@ Lz]__CdR{`L=r85v&mQ뉑8ICX=H"Z=&JCjwA`.Â?U~YkG/̷x3%o3t\&@w!H'"v0PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!)itheme/theme/theme1.xmlYKoD#FG*$ i춨Y{֞fff G$$DA\q@@VR>Mԯfl'4"@Э߯8L'BRVHfq/7ܼ pa3 D7V}:^V I \ƽ Q*_!,cy$gc.RVs@7esVka.4 PS {wh^2`n^.L5qW @90-0[~i@I ~w2;Yd/5j {9nt<d |gk@ ^݇fA9:_Uhc)'lYr }ðRӜqnj 2'v)% P\r q>w_8b0)(=BZ̧:wy&(HqUr0a!x:&HsW5߂w6.R(ys^G~܇,cߗ{pos7C=g'>%Oh4 d"/Z;E8ۊ|押*7%pǫo:d;ف޷7ޓwVd9f\NOǔ2r[YBÈ6aQ3?R.b$dcY%ʹCYLa`W72HydCaEƴ/KF]M̺5fm+ՉfsUkLsTT6Uʚ0 _ pײ!3i&\E./EVGĺYm|Wy!qYY v&,\( k8M,A/X(y/.&Y onB%lԞ&f/*Qq.Z2>4 WLsw`l^@"?&u-Iήhۢ"bDh&bZJx`Z߈^mkefyjwvp &(w~Ut_*0@YF:_{*P򄆛-6, MM D%(K&N!.Z%Y2UWV'lkJ M5)ǟ{_d(3J=ߜRUubպ)G7w;!f{#)ZN[Z*"zX ;p)&><{GEP|j+ D]RH{5.`Ҥ,b8V+%OAc֒~s\vN.6]؅[۵M ̎(,sqT,G~"ÝɃ|GhZ\2i:}H1ay,aS~(GdtUC뭶[V;ovPU|* >ޘPZXWLv&j2{P|.`2uf5a8 Lc#݄ʟPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-!K[Content_Types].xmlPK-!֧6 1_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!)itheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] K7 :)2)4(( 8YM  4  4 H8m?Rectangle 2"PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!A?fdrs/shapexml.xmlUnF}/XkR:BQCyH.ͭ.ugf (zٙ3gn>nkwR(WZB~Y>"&p5T!w*ʏ7o~Mc'ӮmJt4U,wS,$| ϣ.\MYNޠ)^t@RB:B4,}Rx6JLhWq|7`;OCOߢ7uߴ H:JXV](: [/Td={ 3b|5^>y&S ;iĶގjD'WxT&afم>)2A 0ug1Gm̩asƝjFl y}9d[)DIլ@,c1Mcԧ"֨r흯w,܆1Q/Rl`D`%a_/.bpH^O\oFWB&)x-e~ dN~.SicDJڌq֪yBdž1{J#?ӀfL O,K׮a"gF r9_rHY[݅7ޥ[RB Dvc{8罫<Ai"!vռJb Cp5T~mAo8-{[n_ iŜ2j778]=UoL*\Hξ,23Ͼ. z3KRTIe!*A*?9ځF?H76)̓ Ʉ/9荮iH2_bӐy1ar^ka. sys5P!*GOނөjjl<`-2زWZw O*pPasãm?x|PK!Ήdrs/downrev.xmlDAK0ॸU. .]=ͤ-6<Ƿ\OvCXBBF8s5IL֫ӓ%V>YpPAX ,SgS nQHy#,:顣kmz"s~;{]Ϧd,_ԳVpUe1Ou!W.6XPK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!A?f*drs/shapexml.xmlPK-!Ήdrs/downrev.xmlPKP ,     hdman`  Arial&Monotype Typography  P   V]8Xx  4 HTq?Rectangle 3"PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!drs/shapexml.xmlUn#7 }/Zd;&1vHf[ ؋>sf4պL%/%.2)vV!j 9p.r{-ٍ1x SQ~O4v/8 ٦MGXB;P`!1r f49?8CWn恤y=Bׅ\_p`1싪īQB|W8 C8%`*?M݇7:wXB%,]+ҮCubBRAbl.FZ|Omِ4_|rK+9eSMBz|C uWdFif dم(2A #g1P'm̩sƝFl y{5b{+'gWIm4k4o;H3*2܏r;n#-t'2"3N, Z1-+Wjռ_lX8Af\7^X]@K()[+bƻtϩ&6Db\ Uk6hmT&ݠ-G[޴_'LpxkX׎2 6Z BW!ur[m:s.rg_չǢ̕ミ  )KRTy% iı^F/|M+d—@?>ؒEª6m~9Ԟ s=kB@KmUj#^'ES>ߌx B'=+x'dw*ͱ 7Mtw PK!rgdrs/downrev.xmlDKK1!\MIGqtlZ]'7Cۙop9|om/CXb@Wthx{8"1i(zu|¸F$51jb8uc!m/3.ŎCݵT}ܾYq[{r%7>=77 "|__z6γ<_OߙC$!%d rPK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!*drs/shapexml.xmlPK-!rgdrs/downrev.xmlPK  ,    hdman`  Arial&Monotype Typography  R   V]8Xx  4 N{?Rectangle 4"PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!]fdrs/shapexml.xmlUn7}/ Z8Ԏc!6관jC]~h"~G !T5";DYz-=`]!Ӭ6NF [}ϡO]s!;ǚ =~c3KB (j\^]cYl@]gd 1f9h=7xѺs͈m!oW 8#c˭ kZrRS~q$06u1saQhrݽol<} PRlHDg-$L./cgooʷ7oj!K)D-;E[BIزO~@.SN1-I̔paVL>9 =(Ph0to*V [) %bzaC>Y."Uٝ'SlAe"!vjU8'{]{`|w۲a+Q|0'\T 8m, j5b̅29X9/C'Y#s;dIG-'GњW+)^E&e8ΑF"|՘\k VKsݐ 2WX Lx[[pRt&ZcqU\L&U!j ፁZw!3\8Srm,wPK!drs/downrev.xmlDKK1!\DhelZub N'ɐi .ty8͗l$Il픶XhΒ3X../X)w[webCPwd0L@6wc)MEQLAmC=uTq*Qe"UHR^_`R~7%NfX:V[ m)PK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!]f*drs/shapexml.xmlPK-!drs/downrev.xmlPK`P,     hdman`  Arial&Monotype Typography  P   V]8Xx  4 N,?Rectangle 5"`ZPK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!K drs/shapexml.xmlV[6~`b!Ym%>VNR;.8\ I<ñTl/+yÙԩ ϛykBgB-c~xU ^nT|}5j]pL%5Ɩí}mWV:Tn.E3u(ʲ"CLܾ@*y 05`ĿYqiB(4-xcka+E1m3V PKeTJe]Bb[-C,Gy;f;%O& 2"FܖFvL3?d)h$YY?Js7*bn/.Н6B{S@1*}vH2\PbOH*LgE Tr2GMrF@!} vAypI`ؒxF$kHt[XݑznShpXjzs&)`PpUJ= ,W̿=xz:?5I=Uvs$%"!VWChGb(2FHr۟5FV4 Z|3g@7C\Gˢ4 K{%Jtc Y[` h&irHFӸ_U&[,*pK乌,rFNZ5o  %ǰZ<(B7yL#SPrMQJǖ^L)4gU\}ӊ.+UdY?%E uͮc߸YϿ Sp'߷᤼U _< PK!drs/downrev.xmlDQk0pT(R&ۣ"{6MI$=;|m=5 δN h$֐ynFOk̥nUhYskEdRX1Z.\|e 3A@Z}kЫaNj{(qc+QR|\΁5d>m2PK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!K *drs/shapexml.xmlPK-!Kdrs/downrev.xmlPKO` ,    hdman`  Arial&Monotype Typography  h*   V]8XxB 4 s *޽h ? ̙3380___PPT10.pZK: W PK!K[Content_Types].xmlj0Eжr(΢]yl#!MB;BQޏaLSWyҟ^@ Lz]__CdR{`L=r85v&mQ뉑8ICX=H"Z=&JCjwA`.Â?U~YkG/̷x3%o3t\&@w!H'"v0PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!)itheme/theme/theme1.xmlYKoD#FG*$ i춨Y{֞fff G$$DA\q@@VR>Mԯfl'4"@Э߯8L'BRVHfq/7ܼ pa3 D7V}:^V I \ƽ Q*_!,cy$gc.RVs@7esVka.4 PS {wh^2`n^.L5qW @90-0[~i@I ~w2;Yd/5j {9nt<d |gk@ ^݇fA9:_Uhc)'lYr }ðRӜqnj 2'v)% P\r q>w_8b0)(=BZ̧:wy&(HqUr0a!x:&HsW5߂w6.R(ys^G~܇,cߗ{pos7C=g'>%Oh4 d"/Z;E8ۊ|押*7%pǫo:d;ف޷7ޓwVd9f\NOǔ2r[YBÈ6aQ3?R.b$dcY%ʹCYLa`W72HydCaEƴ/KF]M̺5fm+ՉfsUkLsTT6Uʚ0 _ pײ!3i&\E./EVGĺYm|Wy!qYY v&,\( k8M,A/X(y/.&Y onB%lԞ&f/*Qq.Z2>4 WLsw`l^@"?&u-Iήhۢ"bDh&bZJx`Z߈^mkefyjwvp &(w~Ut_*0@YF:_{*P򄆛-6, MM D%(K&N!.Z%Y2UWV'lkJ M5)ǟ{_d(3J=ߜRUubպ)G7w;!f{#)ZN[Z*"zX ;p)&><{GEP|j+ D]RH{5.`Ҥ,b8V+%OAc֒~s\vN.6]؅[۵M ̎(,sqT,G~"ÝɃ|GhZ\2i:}H1ay,aS~(GdtUC뭶[V;ovPU|* >ޘPZXWLv&j2{P|.`2uf5a8 Lc#݄ʟPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-!K[Content_Types].xmlPK-!֧6 1_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!)itheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK]  0N0 <r( X!`:w < < %A??bcm_logoPicture 2bcm_logo  < # T1?Text Box 3fuXP   hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography  xSeventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) A Review of the Guidelines and Controversies Baylor College of Medicine Med-Peds Continuity ClinicL3-,37  - 3V]8Xx6 < S Ԕ ? +T3f3fy___PPT10Y+D=' = @B +" 0N0 D( ! D D %A??bcm_logoPicture 2bcm_logo @ D # 91?Text Box 3 V   hdman`  Arial&Monotype Typography  j Statistics  - 3V]8Xxt D # :1?Text Box 5     hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography  H HTN affects approximately 50 million individuals in the US and 1 billion people worldwide. HTN is the most common primary diagnosis in the USA with 35 million office visits per year. Framingham Heart Study Individuals who are normotensive at 55 years of age have a 90% lifetime risk of developing HTN Relationship between BP and risk of CVD is continuous, consistent, and independent of other risk factors Only 35% of hypertensive patients on treatment are under control. For those age 40-70, each increased increment of 20 mmHg in systolic BP or 10 mmHg in diastolic BP doubles the risk of CVD across the entire BP range of 115/75 to 185/115. J@;(<>95E>w^"b"  y"m"E  "$$((" 3V]8Xx6 D S Ԕ ? +T3f3fy___PPT10Y+D=' = @B +"  0  0L( @!؞F@ L L %A??bcm_logoPicture 2bcm_logo M L # v1?Text Box 3   hdman`  Arial&Monotype Typography  wBenefits of Lowering BP- 3V]8Xx L # _1?Text Box 4`@ D<   hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography   Anti-HTN Therapy associated with: 35  40% mean decrease in stroke 20  25% decrease in MI More than 50% decrease in HFX#Y#""Y" }38XxP L # ؏1?Text Box 5 `ED<   hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography  R Patients with Stage 1 HTN/Additional Risk Factors: Achieving a sustained 12 mmHg decrease in systolic BP for 10 years will prevent 1 death for every 11 pts treatedd47=4""t" 38Xx L # $1?Text Box 60v^   hdman`  Arial&Monotype Typography  B The majority of Patients will require 2 or more anti-HTN drugs.*: C" C3V]8Xx6 L S Ԕ ? +T3f3fy___PPT10Y+D=' = @B +" 0 PT(  T T  x|?Rectangle 2"PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!M2 drs/shapexml.xmlUMo1#,_QIRڴ]uJ"7YⵍMzMgoL?n[6ºF9U9zw}pʙ*Z'oߜe&+M6r%Zr ZۖQj373f3r~rzz 4Z\{+JXJK[8\ =2|)"W+&.+A ˸w*@ X̊Jx)8os~txvt6>9<;7h𔬋ISm'fz<<A.p9ebY ht2?pV9BtaBe2.l/ UN0:>pvo \Y0&@!>|ľp]k 0R%y~r1in 2|unap FWdD 8MTCsËKZ@RcrcZШ%;iø܀"Ш MK{(< ASuiבZ+w`cջqvӬS%nH$xL9+=P*(q#.E:vOދ"ݕwlk8AC!$7evf{CuSPڦߛ*2ιP_hoYcs+BAy8[  UG%l8 |&Y`hRQFʄ98-*,Fk|u硛.Qj*]@+(+Gc~X0X,BAcyY*OQ}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!zOdrs/shapexml.xmlWMo6 x-Igǂ)[D$ԇ-Ћu!fx,rvfZE|aTdjϯϽ[άj#rdO򏋟/dX켌ιrd' a?R*Rm 04~i ? Bd/:˕!+tXm">rDc_d\1qaN# o78ҿ\O;&o;)6qnl*@%,厹S ޜ8#>MM.cY̏)~^u2=M 6<:?tYxxdxfVt9&YF9HwތJY"<9?TU<ÄJo]c>9WRZ mJc0%#@'މRqXZG)?@m[v'Ө黩B a(٘rы'!?% t^!-s髈! CZm\X$R=9=57hZnOʁVJpJ`;' -UAP(MG<2چb.!u͖qC8 ו'qqT$Pܒ\{ECQp c%a鈫0DLFmE WEV?Fqz, YS6H^{45IWG*0[ٻ)˽oeN&hYa<Ф'lg<]d7}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!\%drs/shapexml.xmlTMo0 tڤi6F m@Pu ٖ7IrIru)dÍLq. Ur҇,Pt-r .K蔮Igo=VK*e5˞6rCFװZ1\MKfnH]tt45{ X N+ 8fX 0a"wTNSMVoQ+JJ@X􊸝JW;)oSz6yw1ZkIlVKrA@$sAEPfOɳaHn8SlN(qa7<NUɶ(aߔP7=d oƺ3xSيi ffmF*a]v('iAD5j!Al@xeV"KUɫ˳}ddxJqg3ykցJIwnN ߾1ѺVIqb^8aT|`->pU{Suڼf6ۿS&,}CbI\@mF=ՑUdR.2"7DRGڦT"U^%J57(oN :+ߟ8~>z[~(UyCүRMk!bD]@Y#?;3^UgڙxjNUcb}kd gEEa?( Dݘw2cXurGPK!@SOdrs/downrev.xmlDAO1$fLi֕B'@ vVX6Mo:MˎC㬄Frfy Yp`r'[qk 6(A圇J0r7S5WO nZ(ĘllZѫ1oYʯpK1U'/"eq)QJB}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!"N$drs/shapexml.xmlXn7}/ Z8ٲ,Xlj `9ȣARV\rKreُ-} =C,Yh:IvIp8sg×\.3/I4ӗ=漿yS=~-y7E =>j.\Za rUkZ.2͏`JGR+y=Z=i78"Dzg2JUzq\;ΤV\!'~0m4S&5WS)RGX\*RL.ؤ/z|y{oU2 bu9'yt(dG\y(Hpver?JiqqC:h.e~jTFv{s=JL^?У"!EΟ/ [0jb\f4 b>pp] QΏ52`Vd(v,w[YÁt;K ./Y*'bϰK&W%aiXEi#]F-!"Ń8q畴*VREHqK6ŝ$bDDfSmdzS,ϒX?{ΊLF'hU> ")f~Kqo;Ds/ *5,PIb v*0Z1-&%jgJD;vsbtUιp;龲:BӉ ] j׉;?@5H=WkoMЂX.|a5<=~~znol6_~N6vntoжdCnc]ކr_ !gM<~ĴNqrZwssQDm<7 S3WrNкҌH֪Qy!uYBW/\Oĥq eR  What s new in JNC-7? 1. New disease classification of  pre-hypertension 2. Start with 2 drug combo therapy for BP e" 160/100, i.e. Stage 2. 3. Simpler approach to risk stratification - deletion of Stage 3 HTN 4. Committee s fine print comment on choosing first line agent: choice can be based on patient s co-morbid conditions, i.e. compelling indication (JNC-7 published Dec 2003) | Zj Z Z))$  $$)H)8@X`x6 \ S Ԕ ? +T3f3f___PPT10i.qsb2+D=' = @B +" 0N0 %d( x! d d %A??bcm_logoPicture 2bcm_logo K d # dC1?Rectangle 3M   hdman`  Arial&Monotype Typography  sNew BP Classification3 3V]8Xx d  |K1?Text Box 4"PK!{[Content_Types].xml|AN0EH,BI F$- qڲAK{4fg`bhlz39,7U=DdQhVN9GLUHe2!gu]]k(#*kzky_O&鴷Vb\D:r g.dUg3Uc8O.͹᭜&9R~_,dgzjǎ?I'f#®Pb-\/Ƿ0Z]nLnp__3.iJV KQBiDžrL,Vʌ/7р4`ANar+m;E/'3U Aںv83/PK!drs/downrev.xmlDn0DV8D(BJ[6^촱&C{\ͼr0-ɇYQldcq2"Z$NLJ9** 6(@ؕZ0rٔ]7o nZgY 665hMS]]U}\+զs/:ijbR@17!lPK-!{[Content_Types].xmlPK-!Z,[ _rels/.relsPK-!drs/downrev.xmlPK $@$ 0d   hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography  Z Based on the Mean of 2 or more properly measured, seated BP readings. On each of 2 or more office visits New category of pre-hypertension has been added: Identifies patients with increased risk of progression to HTN. Those with BP 130/80  139/89 are at twice the risk Prior Stage 2 and 3 have been combined. GYBa"}""  "" D3V]8Xx6 d S Ԕ ? +T3f3f___PPT10+0ÚD' L= @B DD' = @BA?%,( < +O%,( < +D{' =%(D#' =%(D' =A@BBBB0B%(D' =1:Bvisible*o3>+B#style.visibility<*d%(D' =+4 8?\CB#ppt_xBCB#ppt_xB*Y3>B ppt_x<*dD' =+4 8?dCB1+#ppt_h/2BCB#ppt_yB*Y3>B ppt_y<*d+8+0+d0 +"3 0N0  22 l1( l l l %A??bcm_logoPicture 2bcm_logo K l # T1?Text Box 3    hdman`  Arial&Monotype Typography  uNew BP Classification3 3V]8Xxm l # ̉1?Text Box 7DU     hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography  BP Classification Systolic BP/Diastolic BP Lifestyle Drug Therapy Modifiation Without With Compelling Ind. Compelling Ind. 0      $$((,, 3V]8XxB l b1?Line 9v l  ~p1?Text Box 102 w\T   hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography  dNormal < 120 and < 80 Encourage Pre Hypertension 120  139 or 80  89 Yes No Drug Indicated Drugs for the Compelling Ind. Stage 1 HTN 140  159 or 90  99 Yes Thiazide for most; Drugs for the may consider ACEI, comp ind. ARB, BB, or CCB as Others as needed first line Stage 2 HTN > 160 or > 100 Yes 2-Drug Combo for Drugs for the most- Usually compelling ind. thiazides AND Other drugs as ACEI, ARB, BB needed or CCB2V  R   $$((,,0044 88 << 3V]8XxB l d1?Line 11B l d1?Line 12B  l d1?Line 13B  l d1?Line 14UUc  l # 01?Text Box 16zT!0(   hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography  A* Compelling Indications: Chronic Kidney Disease and Diabetes *B) B3V]8Xx6 l S Ԕ ? +T3f3fy___PPT10Y+D=' = @B +" 0 t(  t t  xt?Rectangle 2"PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!ʃ3'drs/shapexml.xmlUMo8/@HmS $@v0#Nc1([5E$}C:,Xfyg|ihSr~(2-kR@$mAyi6f6l0F5V* Xu+( QdPm Gݲ]8‰X C ީ ZS9-CL!ˡr KFQ3"#V݈ph2A+ \OtzoL8Xl_W.(U%z2N!'L(·# ŐA+L,ly+BkuR<8{G SaGWp\.5V4LssYw\\qZa,ۂCpBlB8tkjU el\&*2p#(б~X4jc0w<ԦDE*UuOcbWÅA\m䷲&\]+,n݂~Zt@DfoEĎX*Vx^F\m1 U޻ꮵGfWɼAO[ h t-\'>~T%kѷpVl34mmMuœx?Fz:7x 3C77=OQ8**ۉ7EQ7³a&닇 5qʔ rq:zR"?2}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!$}drs/shapexml.xmlXj9_w]\?1qJvcM<iV']hao6y~GqlS^4XH:?>>xR&ZyM3"=ME8?t9NH}~%-{/y }>s.U6L7: }6pE57JBYZmjj&1ZV~94,ygiqDed'.RɚZ؅!~ t43{q`JnJkVG˙SKj[*J3rx9+W}owb\0Zb=q̰t߮WpjP\9^ou{dSH+>[scE)8&Y^s(6ל]ۿH?YÙR5RDT&TyܕY.@ )Xw(LΨAH{=\zX`sA֍6SѩaB0lnnr|%d$j yr6񹘌C4ڸ0H:6sX+wLӪ`kPV N)ͣaRPŨ۴8-bm9,bk[N w8IT,O$!fi_L뵏aL#=QOZES%)Us3aD}stNL&=lhF"zᅂY?PFϥ|Q=@I/Ț$sxȷ8KZ$y*El&:6*z+}i9hN))}dS<4q r/)~mLUR(N#; vl<ӧxDa-M}GSwN>3V`km/N &z{q _?w7_ngJ {(Q kV*J3<$U~7F鶹̚ ^lr8͛_OszF"(\ ڣ@& = /a|U~u^ȅ6G%7OtZ +6e;eĽ.{2.]- nܯ%y-+  !uɉH?ѴPK!drs/downrev.xmlDMK1E!<86-WVp'ɐ鴿B{93[chp9-S^HؼLJ`1yGa1?=a4S2 %)Qd1N}O.w;,Cu}ێ_-h\~hǖJ ymjUzl|hLcTnEi 7v6]cL$dlMPK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!$}*drs/shapexml.xmlPK-!drs/downrev.xmlPKP  Some clinicians are critical of the new recommendations. Not in favor of creating the new disease  pre-hypertension - feel it will cause more anxiety than aid What do you do for someone who is lean and living a healthy lifestyle and has  prehypertension ? No evidence that lifestyle interventions in this population prevents CV disease, though it may slow progression to hypertension. h9 g  9g>  X`x6 t S Ԕ ? +T3f3f___PPT10i.VrGD+D=' = @B +" 0 |( _" | |  x$?Rectangle 2"TNPK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!xN/drs/shapexml.xmlTMo0 tڤ_Y)EPqm9q#K$i~%0 2%R#mF:!gRj2w)g>] ebӹ{pY*; |J ]m\+n9NzԪp8|Wz۹#k8ӢE[YRIv]"cfʵS9 `|sH1 sa%EqV ŮXx@$mƏl줿%Yc6a{eɹD炊a܎' pꇦl8 q7:FUV鮽6*#t /,mV֊0ӹ-ɔ·p6ܘ|%b3}m r|#AZQ>%:AZf1mQPP]գ(*rUz!|?qB L_u6:\[T0<ݫ;tdE,oyFP|`ŕ>Ewb-|,N#Qr1踍O$imZs$Vqƥ޻1@Ykq4\K&gkPjNz'4'%UCS.Θd4LRoTSa- Б{k'yO/ǪDZR{*P5Xw )a׫XQ V;~LPK! ^drs/downrev.xmlDMO0DHk jSBݪUc?\xD^ڔ_ћۉza@i]a] "3yG.a6`a٭Z$jhBX5d1|O.u,r&9m'JebC=6T7_VC׾o\ݱ\Jۛaib_E 1qX]>Ckl)PK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!xN/*drs/shapexml.xmlPK-! ^;drs/downrev.xmlPKCUe!   `JNC 7: Controversies cont.    |  x(?Rectangle 3"JDPK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!:drs/shapexml.xmlWj#7/n?I^8^.XcOƱs}B  iR{Q-?}g׫\.3ǛIig=fPpS=yuvݢz%s RC +^xzhsiG(#KrdY6N3-r{-$1Sze]dd?Ifj-*<ȃiE)Mi8M^XknRLqn=$U#Uʥ3.LɯzٟO[g'_4F]5bsѥ?KAC=p0[+PVr~TQg>'acT}.+6B'㞳!VbB R5uf^؂Nrߚ\2yu6l#D9?kt3A18s P.]8j F=^X5gSވ.6IG').̩"L8R#>]O\QV=dx{!7sSPw"""m*R`N UUԭͤmS/gRPw`S*0=Y8+2"6-\N Q$1ׁqt݈?Eg1]=.u:C8ֆ` pj3+Ң"^eEHDTٝ|[YcRZSjJӧ6LMHʦ$ ;lupL)roVTp.5#R'|,v=5#O\6S¤m6NNYcm}L߲65WAf{!nO??=ƞ~}ǏZk:f#FF_!Wt$ lcGߕx}$ __nvC( OXŖ ­M~pm~]a'PK!Bdrs/downrev.xmlDMO1E&摸1B+̀ g)LI[_oB7ܜŪ7 8FV:m%c< Ypbr'[RK PY0v-7SWO n>Ͳ[nPPcK5]Ru&wgޯvRap,Rǻabf/M Onr`ת H~6_PK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!:*drs/shapexml.xmlPK-!B1drs/downrev.xmlPK9eR  #Minor concerns regarding combination therapy: If side effects occur, then it may not be clear which agent is responsible and how to adjust therapy. The subset of patients with Stage 2 HTN whose BP could be controlled with monotherapy will not be afforded the opportunity for simpler therapy.6. Z Z. $8@X`x6 | S Ԕ ? +T3f3f___PPT10i.jsm+D=' = @B +"{ 0 vn( '    x.?Rectangle 2"PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!{ddrs/shapexml.xmlTMo8/Hm[ $@v0#Nǂ([5ErIʱ )X:HC͐=\~=t5%|suk6%p{FKWǰل•|+F uX߉ߌWA("uzt>Fh _(_'KWuɿL)gFtH{$@lb|4-8VF0 fLlM]yoJԁ~#(=Oac /ņT(~RiRBK>P$ J,͵%~kUU@-Uo$2d51N+^TƽVSxqo8$f~lޢZ rtܯ}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!dBK)drs/shapexml.xmlZn6;^{c#" ncaY1e*V#Q*E;NY@  )JVEM[ Dg MPYȱ~~{rX\(b]{(Ke6JRtlfR<{B-HT5꬙* @qZfC+SE%zX{;1c {,|(q 9cY e_`=L~VJc&K&J./2"cܦQ**.L*~{|p%wzVF#GSm[|vz;i03j#9|HXo?XfIԕ.V\ EH2q C{mjJ|I$"0.};+jЗ)9K}b٤*'\y%%OaIkۼj ADKGŸ5ӂb&f+DkkP.X0VtG[gW mZ"JC+"EFEɱfm[ B@*$(Xm]Z%h\4_a'Ecij,%W :C{4uGTK |z85Ǟ3ex; 7MeYaj *<2΅r.Hbu^J} nڦ*I*jL(r.4&NpADSQgGJ'n @hwvXM{EeȶLS,F|͟nwP١jcUlUK1HX$oC;F|V5kD#mlmlKF*, ٳ z]HEv.6G/mvu6'K%^,2EpY36DuAO+\>Q2{B/ߦUWXmڣi۞,|$ϣ)deh٨/PeT6|שu6o.3Kz/VzY'?@qd[w;nw;ܗshcր74<ThQeȅ,ˣ LgF"B.ͨV6'ږJMlzU۟d߾WhK*m9۽BA-*Iyp- h"S8>f] @R_K|QKN0-PRŢXO5uƑ<$69@P(|M3dܑgP^^iJ{kD#n]`QRRKZ3J|H3 Zˌ=֙  ,20il*Y'hJ3*0yQb7$._h>\zgQc&'Bm*Pr#n3+D_ۣΌeApH:cE CXLꇹDY F4S_EK+pO?0QsQI9an?g۵7W~=6zV7XGhPK!N drs/downrev.xmlDKK1C7f|1mZ-Sv&8I$Nz ];|uo֑Y Y锶ׇ*l%' ^ +w%uX!Gumy5 cגMy1E_qWY6M5tW4u׼ӢȤ] q>7 `?~6_)a{Z"y/&SPK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!dBK)*drs/shapexml.xmlPK-!N drs/downrev.xmlPK K@  7MDiuretics overemphasized as first line agent. Guidelines too dependent on the ALLHAT trial. ALLHAT had shown no difference in primary end points of coronary events between diuretics, CCB or ACE-I, but also claimed fewer coronary events in some subsets of patients. Hence, concluding diuretics are the best for everyone as first line. ALLHAT not without flaws: patients were randomized to treatment with a diuretic, CCB or ACE-I without regard for comorbid conditions (i.e., ACE for DM, BB for MI patients) Also, guidelines seem to have ignored trials with evidence of ACE-I superiority in younger patients. Thus, not accounting for the theory of high plasma renin levels as a cause of HTN in this population. To recommend a single drug across-the-board as first line for all patients promotes the absurdity that all hypertension is the same. \ Z Z\${dF Nt;X`x6  S Ԕ ? +T3f3f___PPT10i.rsp+D=' = @B +"< 0 7/0(     x K?Rectangle 2"PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!긦:-drs/shapexml.xmlUMo6 x-wcD^$0#΢`$QcRס(vEu!=˾boC&2R@"mAye/wu܄F#_nTK픁[:2.jheQKsevn*owK'*jq*bp,l7`*G aq6u}(&M}ڟ?k4\N&1c4S JOtQc<=!$uՁ4Igo-@"랤xt=9Ц4 !Φgq޸.ӷV>LssYw\qZiێ¬C9p\'؄z ֮6ԩ@,8MT!ڇU8Y$-Qc=01-hԒ[ĴaEC@xhL"&5*>rUSbOÅA\m䷶&\]y l7AQ-{SDfeĎX*V^G\}1 _u[#Ezz6o]-*4wK7(%N4m6$Vq.9B}S<^)Du\\M5[cWђbU0DĒΩ'G2ߺ}Kgm6CӆGcon*^Tu:7C0O=3Qj*ۉCwEQwҳa.Aaxhq2ՒAk^MKwPK!drs/downrev.xmlDn0DVR( BSE6^؎lBVq57B>tJM0Sm%S,D {gI,ws,]ز@ :ơ<4 ȦNrBd`gSƁ֚se$duGxy; }-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!SOdrs/shapexml.xmlWn7?4-KǁmM!,YԈcM5CNIJth/\R8x{I^C^9Jc3bq&UJ3\++i/;dlȹSd$ a_R*Rm P5H+y^5?Pj/{JiϰlV9S2Ad ^.qtu2`Cqn`)#&ї#)1oU!T1wU"ʁ^q?Nnۻ~jEgK? S7kf <^ż5TF#g%G^-i68K5R eʎaQԝjG{́"m94&H_ܨZsW̆inRX6sY(;0VR 9jJc0%":?bڵ(_ [wWؔ_gGC a؀qک!%!tC~Pgbп$D۸I:2cs;}oд1>)MTY9AO2%Mm{G2viܢbqm_8PDǓD%035^ &eayz = crVf."!JձFX A|-9*91{Lti̷*~xRd5 ,ݘKUy v"R P'g5&#RXPM ͽHhRtXٵ|-AwoS*Sh_O<_y6F_1%'V 4پaUg3ƙ[BUr@b E0$vːX2`g;`,,޾,,ȋaiՏc w k99?౷_(Ёؠ*(IO|Ef eլ.Zs2Ku[|rۿw7spTzF7Bkr7]cs?'{>_7E7 O@_-y27Ng%[T<۬e^pHAؒjFA_(Igyx,fLb@*ٿ$}씱n _VQ{hCHiRR%yށtCq% 3nv1QJLnpu2V}Soqx^ 8`ښj% ԃ]kcj3}$^~VǾ)y,y\ Py2}lDµSf&jPNP" w[G3C{ư(i4q^궎5VK +}?/XCe*\0PYc}N L’ @)%~YɐMOCy?x.vd6iH#e@1| 9}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!,|Wdrs/shapexml.xmlUMO1W| !@ H"P7Y]~}M8TU9T݃wfg<gF*}΄*tYyN8sTIR+p|Ù9ðY{3\ }mҶ!{ ''D aZ1BLmԲ`ioE"Ru~i .+#:|USE+ȩ&.Տ A  ֪Pj,Tk/G NN:4K]ng4 ؿzgЖْEq p6<}e_T\i!U n o9Kʕhn "~unaAFbolAFDZMоj"AFAQCvۆpDV%F=$8WRTwϞCάOMԥ]F|+Eܕ ȨΌa01VȐ@P3ŴlEp?|q)[7^T7~5o[GdvN]IIOkT޲\MUCiRUZ4Ӳ.#g+7QUζ8Ԇ8YJE*}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!y"drs/shapexml.xmlWj#7/n?I$w f1q XHSIع>Oimy~G?R 9::;$eBZ75ΤN8.xݫ8s^PF._Iߝ}iq9`:yϼ;ժKf2ɥnbl&!IڋgyYOdZz%7IР ubט8ZnD]щs^dif~LcnK]8R׉-X,06Dm:G C(51WZ)ХiGT|D-Xc&ԦД6Tu3v:zߦfr2ơe ?e;-tE{ )"q{đ?c777!)2\^Ik75_-9'F ?+D_0UHW4'iHQx$4zwLܟu4F?m!M;YZ\DxuzJ yYQ0 /#{}za['D^ lf'1g2Q#Ze4?%"Zjh0K욄( fQ>K"Z\v lX\̫ħ4N5:#k0mS\,rq%5ڤ~m,&.%gb$ qxK¤wwj|d t9%k1JD* ]YXqi̔UПYF 5VusYt#LE#:g d+bQF+*!`R+8vjr r0e,27n.SSƹITYf6'rPOa25yNSšӵE6~w[a _v RrKDnHR169[;ryɏ~OljsG cw[ wr#Td1N{ؿ7zfz40zfvkzя7pMϮ<(WWz=)shPK!jdrs/downrev.xmlDMK1E!60 yo) show best responses to monotherapy with Diuretics or CCB, and decreased response with B-Blockers, ACE-Inhibitors, or ARBs compared. Angioedema from ACE-I occurs 2  4 times more frequently in the African-American population8"" 3V]33Xx  pA?1?Picture 4 @@6  S Ԕ ? +T3f3fy___PPT10Y+D=' = @B +" 0  ( hy' M  # @Ț1?Text Box 2b   hdman`  Arial&Monotype Typography  wPharmacological Therapy- 3V]8Xx5   |1?Text Box 3@k   hdman`  Arial&Monotype Typography  eClinical trials show several drugs decrease complications in HTN: - ACE inhibitors - CCB - ARBs - Thiazide Diuretics - B-Blockers Thiazides - Unsurpassed in preventing CV complications of HTN (as per ALLHAT) -- Enhance anti-HTN efficacy of multi-drug regimens -- More affordable -- Should be initial therapy in most older patients BP > 20/10 mmHg above goal should consider starting therapy with 2 drugs. Use caution in those at risk for orthostatic hypotension: -- DM, autonomic dysfunction, older persons" 3V]8Xx6  S Ԕ ? +T3f3fy___PPT10Y+D=' = @B +" 0 ( (' O  # *1?Text Box 3   hdman`  Arial&Monotype Typography  yDrug Treatment Guidelines- 3V]8Xx  # +1?Text Box 4"    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography  AHigh-Risk Aldosterone Conditions Diuretic B-Blocker ACEI ARB CCB Antagonist Heart Failure * * * * * Post-MI * * * High Coronary Disease Risk * * * * Diabetes * * * * * Chronic Kidney Disease * * Recurrent Stroke * * Preventiono=   !B9  +$$((,,00 44 3V]8XxB  b1?Line 5!B  b1?Line 6!B  b1?Line 7!B  b1?Line 8v !v B  b1?Line 9 ! B  d1?Line 10B!BB  d1?Line 11ttB  d1?Line 13w w tB  d1?Line 14ftB  d1?Line 15tB  d1?Line 16tB  d1?Line 17t6  S Ԕ ? +T3f3fy___PPT10Y+D=' = @B +"  0 0(  L  # $l1?Text Box 2UiW   hdman`  Arial&Monotype Typography  vChronic Kidney Disease- 3V]8Xx.  # Z1?Text Box 3X ~   hdman`  Arial&Monotype Typography  XGoals: 1) Slow deterioration of renal function 2) Prevent CVD Often need 3 or more drugs Target < 130/80 Drugs: ACE-Inhibitors/ARBs Favorable effects on progression -- Increase in Creatinine of 35% is acceptable Advanced Renal Disease: GFR < 30, CR 2.5  3.0 mg/dl Increased dose of loop diuretics usually needed in combo with other drugsNAm2kd" d3V]8Xx6  S Ԕ ? +T3f3fy___PPT10Y+D=' = @B +"m 0 xpP( n' J  # D1?Rectangle 2    hdman`  Arial&Monotype Typography  rSpecial Situations- 3V]8Xx  # Ћ1?Text Box 3"4   hdman`  Arial&Monotype Typography  \LVH: Independent risk factor for subsequent CVD Regression occurs with aggressive BP management -- Weight loss -- Decrease Sodium -- Treat with all classes of anti-hypertensives except direct vasodialators, hydralazine, minoxidil PVD: Equivalent in risk to ischemic heart disease Treatment: Any class of anti-hypertensives, ASA ]]" ]3V]8Xx6  S Ԕ ? +T3f3fy___PPT10Y+D=' = @B +"c 0N0 VNp( X' R  # 81?Rectangle 2wo   hdman`  Arial&Monotype Typography  zSpecial Situations Continued- 3V]8Xxf   |1?Text Box 33!   hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography  8HTN in Women OCPs may increase BP --Risks increase with duration of use --Check BPs regularly --Development of HTN Sufficient reason to consider other forms of contraception Pregnancy Methyldopa, B-Blockers, Vasodialators are preferred ACE-Inhibitors/ARBs are contra-indicated in pregnancy and should be avoided in women likely to become pregnant Children HTN defined as BP at 95th percentile or greater when adjusted for age, height, sex -R/O Causes: Kidney Disease, Coarction of the aorta Tx: Lifestyle, reserve drug therapy for higher BP or HTN resistant to lifestyle modification. Drug choice similar for kids but with decreased dose  "" "  """"" 3V]8Xx6  S Ԕ ? +T3f3fy___PPT10Y+D=' = @B +" 0N0 <(  P  # ƛ1?Text Box 2(d   hdman`  Arial&Monotype Typography  zAdditional Considerations:3 3V]8Xx  # pЛ1?Text Box 3X:~   hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography  ^Thiazide Diuretics Slow demineralization in osteoporosis --Use with caution in patients with gout, or h/o significant hyponatremia B-Blockers Treat Atrial Tachycardia/Fibrilation, migraine, thyrotoxicosis (short-term), essential tremor, peri- operative HTN --Avoid in asthma, reactive airway disease, 2nd/3rd degree heart block CCB Treats Raynaud s syndrome, certain arrhythmias Alpha Blockers Treats benign prostatic hypertrophy Aldosterone Antagonists/K-sparing diuretics: Can cause hyperkalemia and should be avoided in patients with K > 5.0 while not on meds N7"""  " """ N3V]8Xx6  S Ԕ ? +T3f3fy___PPT10Y+D=' = @B +" 0 ( 85' c   p?Title 1"ICPK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!m%`'drs/shapexml.xmlTQO1 ~ub-q⊠ۤ U\/k,ɕ~vre4HMcr*7F3+g>@-s_N>~ kٜB`J?+5jZ:0Qp2:?#dx0yGcUv^j701e+6nٓu=Vs2Y,*|i];5X`͹LMB rza 2# X63QMTPCvw҂i0{ أ,])B],G/N䪒b?pB: a:[<5 {z3: dE,o\jux|q-뷾7ZID1^eCqu9x6"{M%/PK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!m%`'*drs/shapexml.xmlPK-!(o5drs/downrev.xmlPK8Ue!   NBeta-blockers out of favor     x?,Content Placeholder 2"PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!o֑Tdrs/shapexml.xmlXn6w x[I&F1uQu^DŚ)R#)e_,6m?mQeL^FycLPGt }Ӣg ά-zͦg"Bا IYI6ı˭3btnj9I{iPbCӾ5 Vn6ݬ;8mBa"P'/j܂_._;􁜂M%PK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!o֑T*drs/shapexml.xmlPK-!+awdrs/downrev.xmlPK|eR  Classic beta-blockers are no longer popular choice due to results of Anglo-Scandanavian Cardiac Outcomes Trial (ASCOT) published in 2005. Found that regimen of ACE-I/CCB superior to BB/diuretic in cardiovascular mortality and all-cause mortality. *  ,K 8@X`x6  S Ԕ ? +T3f3f80___PPT10.]^9"  0 i a  (    A??.art-schroederPicture 3art-schroeder.fig1.gif.3~D  D ?TextBox 4_0(   hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography  $Meta-Analysis of Beta-blocker trials2%$g$c$ % V]8Xxf  J?TextBox 5   hdman`  Arial&Monotype Typography  fNo study has shown reduction in M&M with beta-blocker monotherapy in HTN patients compared to placebo. ggg  g V]8XxI  J '?TextBox 6~_g   hdman`  Arial&Monotype Typography  QBangalore S, et al, Journal of the American College of Cardiology, 2007;50:563-72RR R V]8Xx6  S Ԕ ? +T3f3f80___PPT10.a.U" 0 ME(     p< ?Title 1"yPK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!gdrs/shapexml.xmlTO0~(#"mR*i8mVll0xw]|޵muV9}r&TFr}ys3IU$9 ?O߿03 Lޛl0pZ>j#t-ylj`pByx8 Zj•.-k9S"RdJ? _@TًL/)FKj .'4 dlW8f}6<9x8#γlx<}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!HCZ#drs/shapexml.xmlXn7;V~l ঀ jkm%$W}t'ho+#Ap=Hp83!W/ MdL[/"JLT;=iSb,)J^pC_}a90%dieLg֖f$3^0B\B)]0>o.-Xv%=)cZɛX<%XrL2,3%RI6k0Jv}KfoT?jr 4?+$[9c^8S"տBl'+}I͐MK4D$ ۋPb}#ndU p&؍]5=LOTQ2;2q.R{|tI\7j2c% l12!Έ0vb/oR VoL{c$d2abXi0qv JR2r 8c=i@W~Δh+k1Ϙ<qƕLJȶpw2',CxV'؋g51}(])4Mf'hs3 G|5}!FpL[ ,M۱+%l^t^y~HoLl(B4`@=vYsx*ķ(s %j- IWE~_t/k2Nsm&FMa3oy,{Ku B #F6t}ٜX}(жK9>X#]\c<Tt4(>:fmxzg||2_U`W7f={q8}Wݎ ~ƭYwLMF^q6{9ZV {?Z`H9?~L6!).IYZدJ3 B8. dM^Sٷv^d QP߰~#-W F$2O/A)Αlm]0C_7G4 +^?ʛb&GY R(k m ( Xg2jz{iT/Og=PRmRE8X&hm喂g,oZq!:X*s w[^(u]u|;:>L/ ה+#+)w~ WuN̘prNY3yW@,{}.]H9 Ўbك@zyv?n5.ss/a)o}<ixl/҉;,T~kYPK!<`drs/downrev.xmlDMO@E&#q'ӊ Đ?"G[輩3R7̗EGWqnuŅ=5֖I<,9fڞyG>"Bg ɤyI6ı;Xg0 #6I&`ĆV%}kZl^Y{wqxnoi|g:_ԳV0qx|Jr [4 ?PK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!HCZ#*drs/shapexml.xmlPK-!<` drs/downrev.xmlPK en  IConsider their side effects: Metabolic effects: worsen insulin resistance, dyslipidemia Increased erectile dysfunction In antihypertensive trials, the atenolol arm has consistently seen increased incidence of new diabetes in the range of 30-40% of patients. This may explain why BBs do not actually decrease CV events and stroke.X Z  . >K @x08@X`x6  S Ԕ ? +T3f3f80___PPT10.`I" 0 /(     >?,Content Placeholder 2"e _ PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!/$}-drs/shapexml.xmlZn6w x;ĈR40 NˀX3Ej$:L؀ M&W9$\lC5N*_X$!yx>~㗫L%&U2%\F*NeHߝ5)1ɘ %yH/O~8@eiyHgfD31B\,Q:cknBGh[~3c'Д\NTf9$CڡD *i& 1פM0b>8!Ra@vtI ;g`*Q>^*cܰ`졦J];n iݶ3 ʒApzf*ArVzSмmNU|O ~ a:Yה| i~[0)Huͺ\2zK4E6T1!LFnHmZ8U3;;5Fn7R}Т$U0׊&JAZVB=pz&C\Dz-.m=n8yx?7|.?w4O*}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!.5Adrs/shapexml.xmlTMo0 t_j)EPرe9q#K$I~HaA&E||tymHs~yșT^~1=ʙ+PF˜W.m-g6l6x-Jڸn9NzLԪp8h>PzSع#In5U8bEd|ۓ+`k߃Q9x^g|sXBL0`4bv"@P8"їsBwa]~'-7J =jb(EAm"rA-D*Y/,)g.fƭ#:*SNތW8N ̐HV8VE`VQq7~{pu_o-rmd82[|K22.?u.diAj]۴Ib9rV&\c z\ƛM%ah8^4R^~*zƢm\5.0QbDB4LoTSfd-Kd)es[^ɺ"f8!65}m#EZ4jli]Sy;~[ֻ.v4klTj<V " +Q;` ⲽy"y-&KPK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!.5A*drs/shapexml.xmlPK-!82drs/downrev.xmlPK5Ue!   A Beta Blockers 6  S Ԕ ? +T3f3f___PPT10i.[@+D=' = @B +" 0 (     ?,Content Placeholder 2" PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!PN0drs/shapexml.xmlZ]o(}_iuIQ4RwVFѤyo0xg=/VHIg|M!Țk+].)_/(1ɔ %yLo42Kkqc%/yJ.!˔.EV?uJ YtTNu Kzz^δK%3M4}J$+DId&X—J\ڡ"5SLm/&}8!R1u4IX:-oAzp=]kݠJ?,6dxi7lQ?Q4yؘo,I n; TFn ʱܩٵ~ 1, %47_Ӝ4k`gh/U1QaBLnLmX8UQ2;2qn46a钸$*=|Jzjy_g#\#ع}NA7嵭FP?,@wXKpF.S&O`$[_mTws}u8@[Y'gVo zg)Ybɚ9׸ٱ.V*i|n$j颚ݻ%#,X\ꙿYT󗭍ay|=Ns351QPR6Y޳"`E0L&(1S6l&gon)a g`{cŗ9_`9,Ynm J5)JV\kG ǼZ˱E-"}ց ʹRO&JMa'3ߢXH>" %%:O-WY۸ʇYک~![!/ HY$H'u%!ՒǺMʿ#!iLRۀk,XOVx"YAiYs5-gSSRS%J˓s\':Y~i kF-΅CHA;UH뉺X53KpBwy |Ut>8>}%w_77׷ϔhJ!<$R`,wP>`͘| Χ&V5YRFtN(Js2%84< |j^ʨǃB!ԐdD`0RoKZBP9W>~<92!)yqa8N=J×a2(*;jJB9[7B۴V wIZg520iK"q̋X<j5!  ֛(PQ3a 6A5Y}g;$HeDU ۈˏh4D|I]֥(a+<\u(HWoŷԸAXU5 3J܄G-J⚟qhji1q,ߟPt8>#j/=nHȟᛞo56_Ew?}l/}ɿDwGwtVU~ :zPK!drs/downrev.xmlDN0EH5HS@@C UB<>`?I {W\|p)ڳ(E\x[si}xq* 38Rd^SR% T"mu,*rG%Nb( xHp,kNtstןm\s~6<܃V_Գ5pjt܅ڮ1 -&KгPK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!PN0*drs/shapexml.xmlPK-!w drs/downrev.xmlPK{ .[  ykCompared with other antihypertensive agents, including classic beta-blockers, vasodilatory beta-blockers (carvedilol and nebivolol) are associated with all of the following, except: A. Increase in erectile dysfunction B. Similar or better response rates to therapy C. Fewer adverse effects D. Minimal or no dysmetabolic effects E. Reduce resting heart rate    $$$$  $f$PN    *8@X`xS   pv?Title 1"F@PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!.5Adrs/shapexml.xmlTMo0 t_j)EPرe9q#K$I~HaA&E||tymHs~yșT^~1=ʙ+PF˜W.m-g6l6x-Jڸn9NzLԪp8h>PzSع#In5U8bEd|ۓ+`k߃Q9x^g|sXBL0`4bv"@P8"їsBwa]~'-7J =jb(EAm"rA-D*Y/,)g.fƭ#:*SNތW8N ̐HV8VE`VQq7~{pu_o-rmd82[|K22.?u.diAj]۴Ib9rV&\c z\ƛM%ah8^4R^~*zƢm\5.0QbDB4LoTSfd-Kd)es[^ɺ"f8!65}m#EZ4jli]Sy;~[ֻ.v4klTj<V " +Q;` ⲽy"y-&KPK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!.5A*drs/shapexml.xmlPK-!82drs/downrev.xmlPK5Ue!   A Beta Blockers 6  S Ԕ ? +T3f3f___PPT10i.[@+D=' = @B +"W 0 Y(  l   p8?Title 1"HBPK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!Vdrs/shapexml.xmlTQO1 ~ub-q⊠ۤ U\/k,ɕ~vre4HMcr*7F3+g>@-s_N>~ kٜB`J?+5jZ:0Qp2:?#dx0yGcUv^j701e+6nٓu=Vs2Y,*|i];5X`͹LMB rza 2# X63QMTPCvw҂i0{ أ,])B],G/N䪒b?pB: a:[<5 {z3: dE,o\jux|q-뷾7]^\b5Ft`:)@W^[| bBx&#EX-ooXj}Ep,QI-!q[ܝ}pr  wœth9?lPu8nZl.aۏRD!]_l?F+8Sz1QPݲiPK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!V*drs/shapexml.xmlPK-!k4drs/downrev.xmlPK7Ue!   X$ 3G Beta blockers    ?,Content Placeholder 2"A ; PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!u00drs/shapexml.xmlZQo9~?*e!$(A$TYag{)ɯolOFU!ڹ,[H Sp&uf~Hۓ Μz*2OqU]Y~UrL}4ԐƖ£jZNj/<&*U$V) ͯ1^Ru13-JL90ڣ')əQSiYVڱ5C$LZܲił4A+ӘaMZ`2ew޹<[Ftz^ en˗v}%&%g=>M`˥gy *$Iєh[3}'#B}Vr֝5*vK4E03r5tLY ?*#EZMe[bTD'D%X '7uC5:QΏ/u ,/% JaSo j/0)?i4zgS߉)ЦNR 7g"τ~qF0K"ד}Fg AMmj|Wa15>~Wz+(S D fUu&imcϤ™d\X%BYUlv+BQ'v17Ix d#Ч%4\Ӥ$FvoJD?>.SDޔK}} gmx֘r-Tq(q6X%y+-b4%dU6;~9XYO̩T8䭜b9Zbkw _5G) )3{u7FW$4ݯtNz[e\>*'.]H[ܨ/qLWsnL7V1n0BԡH" 3u~cGSR+u6+vtd 8$~v~J́aB/ `6Nb=ibӶtF&ӂ'EP!%fVAB JwcQ2A-C$U@I |7ar^V*82 ?Dž޲b< c]3Y_QlXi_*%+1‘P  !1uB#Ӡ7Q9SGjKԁǪ:d_ŋe~'fY~nV򕒒[6A+(jSƠ Z?l_J2"z?ѣo+X2k4ePK!4,drs/downrev.xmlDN0EH5HS@@C UB<"}|O@^܁Yck)rqz2\ہob%C ].e(k2&no8$ieH j*7Qk(n?Rg=Hc Go_z @쟎k L%PK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!u00*drs/shapexml.xmlPK-!4,,drs/downrev.xmlPK0 >e  ~dcarvedilol  nonselective B-blocking with alpha-1-blocking nebivolol (Bystolic)- highly selective B1 blocker COMET (Carvedilol Or Metoprolol European Trial): after 5 years of tx, pts on carvedilol had lower rate of onset of DM This study also showed carvedilol was superior to metoprolol in heart failure. * P P 1 &  # 6  8@X`x6  S Ԕ ? +T3f3f80___PPT10.[d"^ 0N0 A9( h    ?,Content Placeholder 2" PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!b!"drs/shapexml.xmlWn7}/ Z(Y-x!rǀZ[q[R$?:S@ / JNzA6mj%93pY*Wl) gREˈ8oqfЉP_K˟~I9%23Ai̅}RRC&]s,R;PVE)I96Ԋ_,džeIĻica,XX H:YiCoFEVbXxT n(xz1)8RlvPMFd)RXd1')`xp뢸5zZTn;`ٽ_g}_R#DC:fO?U+{9~Fo0& [6͖ gPK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!b!"*drs/shapexml.xmlPK-!ɩy drs/downrev.xmlPK| _+  0All of the following statements regarding combination antihypertensive therapies are true, except: A. When BP is > 20 mm Hg above systolic goal or 10 mm Hg above diastolic goal, initiation with 2 drugs should be considered B. Addition of a drug from a second drug class should be initiated when use of a single agent in adequate doses fails to achieve target BP levels C. The combination of an ACE inhibitor and CCB lowers the risk of cardiovascular events compared with the combination of a beta-blocker and diuretic. D. The starting dose of most fixed-dose combinations is typically the same as those used in clinical outcome trials zc   [(($  $8@X`x6  S Ԕ ? +T3f3f___PPT10i.Xp+D=' = @B +"c 0 ^V (     0?,Content Placeholder 2" PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!$_-"drs/shapexml.xmlWn7}/ Z(Y-x!rǀZ[q[R$?:S@ / JNzA6mj%93pY*Wl) gREˈ8oqfЉP_K˟~I9%23Ai̅}RRC&]s,R;PVE)I96Ԋ_,džeIĻica,XX H:YiCoFEP7BW=͒coew/@R%8]t~{7w<}Zu^#Vziz(8!n*4qC4P,lU#P<,/~iHnso85%-7~ 5l(@܃ ̏FN>(Qꕬ_ ˽|ױռ~J#ߑ0Զֈ>ى>`x{IW_Vc {yR*C3e Pq[rս f7MqՔ'PK!Ddrs/downrev.xmlDj0EBw$%@B0&kHc}Dr/rT%K qfuɹ+ˤ'Sm/vr!STPPR ~`k3bt/n*$#iP`MӶ1 9˯v<'j+u׽ԅq<+QZGJA)n4Z]PK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!$_-"*drs/shapexml.xmlPK-!D drs/downrev.xmlPK _+  @All of the following statements regarding combination antihypertensive therapies are true, except: A. When BP is > 20 mm Hg above systolic goal or 10 mm Hg above diastolic goal, initiation with 2 drugs should be considered B. Addition of a drug from a second drug class should be initiated when use of a single agent in adequate doses fails to achieve target BP levels C. The combination of an ACE inhibitor and CCB lowers the risk of cardiovascular events compared with the combination of a beta-blocker and diuretic. D. The starting dose of most fixed-dose combinations is typically the same as those used in clinical outcome trials c   [(($  $t$f8@X`x6  S Ԕ ? +T3f3f___PPT10i.Xp+D=' = @B +"Q 0 LD0 (        xX?Rectangle 2"PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!ڰ93drs/shapexml.xmlUMo6 x-H⬅ȋ$@F`Y%֚"Ur}C:Cΐ|gtehSri(2-kׇۓR@$mAye/m[gm.7!`j2U50tAW&PAɠ2eplwuh 58^J堏KK8 0'd0wTF8lpr>mq Rr9)S xFp< aBfam/_$`\u{w0ŧC,7'iKɍiA< >zCmJ_4IQ쑫RUZ>'GS)\H ͵F~+kU\"ςM\-Eg H8m(K oۈkU}=a {Wݍv[>HepCܔ,@k~8ʜ|]A .Du|w48h.%V9)MS8duͭ7ڊm Nӌ.y2R+Б0UUGyxގ^WQD5Nt[ }p(Jp(-3x%+G켄3R\#ՄE_5_KJmj~x~`vPK!^drs/downrev.xmlDN0EH5HlaQP@Cd;S'mlGЦ|=sGLđbj0R jn ' gJ0]_M4Wt\S澔2 9LГ.DcD}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!^<drs/shapexml.xmlXn8}_`"%c$@v0 #Nǀ)[kԒ{f(ɗE@ B"ϕٺ+rg֌dC[ mr$<ܝAʭ#4rKgHB(OVP-.P[J6AlTnk*3rvVNQԉl1A{Б¨A,s-e. qLlU0p '#h4zD}I*\/؜NCcaPNCibɿ?赀Y"œSHw"P۸>2TC6e;&o8:-J&fV&dH)ʕH8!=lJj;!&eo9ErfMIhPB y;s-ddfYm%K郚^b:BtjbnܚӜZg< 6r$%f;S|LI[e\CE: Ѯ79 WOL `gfDw6 1gùJ8$I/Edu,:.ZnH@7C4Q<"SWM57s)*"#ٗ3Ju!ci4]FΘbJM UV <{1KE~κ6%B ݍق̸I}tbyLÎu*; ,1Z(ğ(O t c#_wL$ JvjdJ;9i?wskB;A~䇐B G&LS#?x?7W4lpQ*\"lX1|"CFyclk!>6Om̓' [jgyDpcpGꫜYWĦٚVE NlV9x84fU*'#'6#ɷ1mS~9?H]|͈W?>W_PK!drs/downrev.xmlDMO1E&晸1ҢH!hf}4LI[_o7ܜ鼷 (D㝄@#6z;:w$Dˋ)]I6U,C\,PBR[pUMrb1T\}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!Moldrs/shapexml.xmlUMO1W|hB @Xz%^۵!lo prg{ٶl#>gB2㷋Ϝ9O$plݩ;pY{3\ ]mC[+P<57j'p6s3A*732Q (R 6.]!1uП$SZG/`J(1 Ĺ~%tq{1] \̊,}~x44t5<<Pto/t09q_Z>rvo e-Y$'PQg>'qc_}jK-#8 x-gis鱇B7TMLC=:~'kXk=_р6SqNs [D'!;eC"PEKU)DŽ3ASuaJ+oax2SwhLU"$e@<$Юۦn]PEvYh^u\ی+kDQl-,^AgG*'Y?qurQ7ZWAIVj)Se]]# f0v8S?Yc}hlX+(+E:mO؏/<:p5"/T9#K`% ' 6[3ia5ԇPK! n`drs/downrev.xmlDn0DkzMR0*jK$.~}͗nٕo0 `dJSI8oS`>QZCa<1Sft=EJC2}YF?؝btWo["D56&.Ѻrʹg x8^m'|@}^yR_ԻI9o'ר=@NBDh |PK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!Mol*drs/shapexml.xmlPK-! n`Vdrs/downrev.xmlPK^Ue!   ] Noncompliance"       xt7?Rectangle 3" PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!p NUdrs/shapexml.xmlWn7;l,7@P+JڊKnI,j^6h \rVy@ ꁃwZo3d5< `wTm.K6B'垳8+1Y.|O ):x'lhErߘT2yyu6r%*`^T(*l%{WVBM/HoppPERFf( ѥx `")>'ijv(txBMAIh ߷ݲ+R ؝zTJka1[_(ϰBށMcQ$"Ydz%T-k $h`O0:y1gLtu`79+43@˥TGub06 lHѦ3D 8IR#xS:J Rm]314JZՏfQ&`'5Wx661 op¶)#R))G l#/ 07Fp_3^;>ne1 k#:[z=:*>=||zĞxx}'_d8.[=,cr%AE6n8z\eSnib(߇kx?C tݣo]ZWqv>QN0WTPTRšm]5u֖㢶{H q N7|XL6lh}Hz j)@:ZD $!>,k4XHʈ`ra$΄u {6_v[m(1 V%|.a6aK95PEDP9\d\!=38}f|QB?ː:QSFGkF/|dڲ`5 /;+>&ԣ( ]G -@ɵJ$xԙ{3Qݲ~e?_V X.|t~Z"y/&SPK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!p NU*drs/shapexml.xmlPK-!ϼdrs/downrev.xmlPKeR  HEstimates of noncompliance with medical treatment in general: Noncompliance causes 125,000 deaths a year - twice the mortality rate from MVAs 30% of hospital admissions for people over the age of 65 are directly caused by noncompliance. Half of all prescriptions are taken incorrectly, contributing to prolonged or additional illnesses. Noncompliance increases with the number of meds and doses per day; at 4 times a day, only 40% get it right.F> Z Z>)~$$ 8@X`x6  S Ԕ ? +T3f3f___PPT10i.sғf+D=' = @B +"  0   $L (  $T $ # U1?Text Box 2   hdman`  Arial&Monotype Typography  ~Improving Hypertension Control- 3V]8Xxh $  |Xk1?Text Box 3     hdman`  Arial&Monotype Typography   Models suggest that even the most effective therapy will only control HTN if the patient is motivated to take meds and to establish and maintain a healthy lifestyle. Motivation improves when patients have positive experiences with their physicians and develop a trusting relationship6@hw" 3V]8XxH $  |g1?Text Box 5 0D<   hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography    hdman`  Arial&Monotype Typography  P HTN treatment must be patient centered. Drug selection to take into account patient s age, race and special circumstances. Physicians must be willing to try different drugs and aim for monotherapy before adding on a second agent.<~"j"" 3V]8Xx6 $ S Ԕ ? +T3f3fy___PPT10Y+D=' = @B +"  0   ,| ( j' ,? , # 1?Text Box 2M    hdman`  Arial&Monotype Typography  iSummary- 3V]8Xx ,  |1?Text Box 3    hdman`  Arial&Monotype Typography   New guidelines are more conservative - new category of  prehypertension Require more aggressive treatment tailored to particular medical condition - encourages starting with 2 drug therapy for BPs over 160/90(H" 3V]8Xx ,  |1?Text Box 4 ~   hdman`  Arial&Monotype Typography  O Effective therapy combines lifestyle modifications, exercise, and drug therapyPP" P3V]8Xx ,  |81?Text Box 50   hdman`  Arial&Monotype Typography  Z Must maintain an open relationship with the patient in order to provide effective therapy[[" [3V]8Xx6 , S Ԕ ? +T3f3fy___PPT10Y+D=' = @B +"J 0 4L( ' 4 4  x?Rectangle 2"nhPK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!Ldrs/shapexml.xmlԕMO1,_+ @mEc5Mxm$ _*{pƞ|DgƿPK!3jdrs/downrev.xmlDn0D֭MUl0QKj!b;]Z]r43:ՠ;v&[k$GҪhv֐+yX-){1;:fb|s_6яlO&vuC%u!&\ckC=m*O0yKk[|_֡ӯéBa=hG^*O%a6MX]v9 /FS?PK-! [Content_Types].xmlPK-!1_a /_rels/.relsPK-!L*drs/shapexml.xmlPK-!3jVdrs/downrev.xmlPK]Ue!   Z References"   p  4  x?Rectangle 3" PK! [Content_Types].xmlQN0 #QI!v:`|mDDq(n쀄8~ZQ̘_˕*@ou2x cX=\7v=r9iMf H']Hd.S#wQ_6gȋl;}tt)eU-!lT/STOl<9R~Q&4@Dƨ*j"t3D q>}-^p>rr‘ܼlb!\}PPK!1_a _rels/.relsj0 ѽqCNo^K [ILcX&m߾0XFo;>0xM e`|X}đ I`߽N4aG2$RKIZ)4(M9`ctB{m:f@`3n|O,ܗr޾jxR0T ,0@}WBLǬ5vPK!qwYldrs/shapexml.xmlWo8~?˯'_-tV$B}D&8#sC~c'xvnU\HcS"LX/RQ3ZL+]C[0LVvXD|\1l6mt!t6pe0JFyZf.RoL^e31,]D|\u9S"Ƕ2L.oVvacm/,x `Jip6+&oO+)ط}Up|)V x9׋ۈ_t^3c,rV,?͵$aغwٺ_rxirA ֱvj_m ^u &?fEp&Pvkiٓ[ #9Vsƙ#H5?T2יMFq#Lu^7V"&C:Ma{~`$EOW@l凶~E2nAP<=u6Z,0 3F^1FlFÈ7j -g <9ЦƅIR՝Y{ܭ3xCNJ)s[R%-IF`ف':@|hp'SS>DċmNm}5Uyy!Q!$1T}z"ky9}޻3/G8ODHo8$IYx5y!v!J ɇ!∫ sbbL TFUE |hgG0)mkO3`!U:KN`?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGIJKLMNOQRSTUVW`Root EntrydO)PicturesACurrent UserPSummaryInformation(PowerPoint Document('DocumentSummaryInformation8H